var title_f0_29_464="Kraske prone jacknife position";
var content_f0_29_464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Kraske prone jacknife position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_464=[""].join("\n");
var outline_f0_29_464=null;
var title_f0_29_465="Nordic lower descent";
var content_f0_29_465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Nordic lower: Descent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During the Nordic lower exercise, descent should be steady and gradual. This is often a difficult exercise for those with a weak posterior chain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_465=[""].join("\n");
var outline_f0_29_465=null;
var title_f0_29_466="Apical 4 chamber echo tricuspid valve vegetation";
var content_f0_29_466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/70221/endtv4ch_conv.mp4?title=Apical+4+chamber+echo+tricuspid+valve+vegetation\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical 4 chamber echocardiogram showing tricuspid valve vegetation in patient with endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 428px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGsAQQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5/wDix/yVPxl/2Gr3/wBHvXKV1fxY/wCSp+Mv+w1e/wDo961fhlb6BPaamNSm0yLWDsFm2qgm2x/FnBAz069OMd6yr1fYwc2r+hrRpe1moJ2PP6K9M13wXcX2p6rC9tY2OqWunpe29tpoLQXse4hnTJyOMYHcjtRYfDizn8RanpZ1OWefToImkt7dYxNNK4yyx73CkJxkk+2K51j6PLdvz/L/ADRt9Sq81kv61/yPM6K9Rbwp4esPCviB9TfUIrmzvY4Vme2xLGGQEKU345JOT7AjOaqReALB5YdJOqXA8RTWP25YhAPIHyb/ACy+7O7A64xQsfSd3r9z7J39NQeCqqy0+/5WPOaK9Ym8GW+unw2kAisoI9BW9u5IYkDykMR3IBY5HLH6muQ8deGrfw9NYtZXhuILuIvsk2ebCwOCr7GYehyD/KqpYynUkoJ69iamEqU4ub2OWooorrOYKKKKACnDOOM45/8Ar02nYycd+gAoAOcfxbcfpmjnvnp+najAz0OOuM9qMAdf0oAX5s/xZzz9aTnHfH+c0becd+/p+dGOO/8AhQAc8ct04+lTWsRmmCHuOQTjIqHAxxntzXp/gbwxYTeG3u7mRm1AvuMEkWAqdsEHPbPTvigDh4dHkkLB1ljONwVhhm+gPbrV+68NJahXnvJI1Z/kxEGxxnJJYeh/KvTdY1TSLCCCFbeKZXG5TIMlG7kHP0/nXB6xfveMI5LligYHDuSpx9On0oA5290uO3SNorwyhh12bQo+uaqNHbxxgFpHc9wQFAz0I6itO8u54bmV18p1OPL444GOO/p+dZRLvMdwLyHsM55x3NAF77AZ7YfZlJLHJDcEY4xk/wCNZPzZyd2ev/1600UQ27MMxkDK5Xk9etUZoJYkillhdIpwXjYqQJFDFSVPcAgj8KAIuQOpH/16Pm+782emP6UY65578UY7d+nXigA5P94jp07CjLdctk8//XoAyOKMcd/rQAc4xzwM0fN/tccf/W/nRge+OufUUY6ZGPWgBQrtyqsw6ZxRRsJ6YGOMFgKKAOo+LH/JU/GX/Yavf/R71Q0LxLe6Naz2sMNjc2szCRobu1SZdw4BAYcGr/xY/wCSp+Mv+w1e/wDo965SpnCM1yyV0VGcoO8XY7bwz45uLXxvD4i1x57l4YWiSOAKgxtKqmOAEGc8elZNj4qv7S+1C6eGxu3v5fOnW7tkmUvliGAYHH3j09a5+isvq1K7fLukvktjT6xUslfq382dVH471zztTe6ltrwaiyvcJdW6SKWUYVgCMAgYAx6D0pE8d64mmLZrNb5W3+yLcm3Tz1hxjyxJjO3FctRR9Wo/yL7g+sVf5n950dr4y1q1ubKaG5QNZ2v2GNTEpVoO6MCMMD71S13XLjWTAJ4LK3ihB8uK0tkhQZxk4Uck4HWsmiqVGnGXMoq5LrTa5W3YKKKK1MwooooAKcR2wcjrTadjAP6H1oAOMnuB+HFGAOv86CDyMH1A9P8AIpD0PQ+9ACkY/Dg80EDP/wBejt2yOPrQPcD3oAs6Xam+1G2txn944U47L3P4DJr257JI3xY2832dcYZ4SQPYfh3ryvwKoj1hb6VnSG2+86jIXdkc+nGa76bxJb2ssrafeSsj5Aj5Vh26jt/n2oA5/WJLmW7khmlDIpzuiYk+3P41mwLbW8EhnMLBslDJycfp7+tZup6lK2qPcRusWeeDyfqR1+tZTyM25wpyxJ3g4+vt+lABeytLJzIrgnjAI/nTIHVZAWdk9Sq5/qKaSC/AzyTxjn9KVSU2lflPQ/Q+tAD7iRN2IMiPqAR0qDOOnbnkUZz1OeMc9qCe+cn3oABjvz+NGABz/Ojt1JHb60cAEdfcUAGO3fp1HWjAxn+tHtgenWk49OfrQAvGenHXr2ox/j1o4z0HXOM8Uf5PNACHjjv35ooPtRQB1XxY/wCSp+Mv+w1e/wDo965Sur+LH/JU/GX/AGGr3/0e9cpQAUUUUAFFfYHxj0DSZItag0aw0+4nsNa05JI7SwitptHieONi4dRulWQt1PAJI/hrmLT4Z6HrPirWjPp97rc8niuTTLpxdlG0+2GCJmC/eLEkZPy8YHNAHzNRX0zYeGfDOr6L4B8L6rpc8rXceux215FdeW1t5M8zhioX94fkA5OB6V598ZdM0yDwt4D1HRdASyt7vR4TLfQuCkswL742wo3SDAJYnPIB6UAeT0V7VdeBfB6fD3SfFL3Mlvb6utlYwhp8m3u/Ndbt2H9xUQMAf7w/HtL74Q+Dz4t8O6ZHpuqwW1zqr2ZuPNYxXlv5EjrIsh4L5jB+T5cN2NAHzDRX0h4C8MeDb6Hw5qln4YaRtc0rV4l066u/tG6e32hGQsn+sYMegGDyBxWT4a8K+HbC5+HDyaVqVtrevalPG0i320WXk33l42FDubYNucjB5welAHgtO9QMj1Fe1XPgnTT4RuNUsNCuvEV7Nc6iL+4S+8oaV5TsIywHGSo35fg9Bya9A1vwL4a8QfEDxXd6lZXGp3dtNp0P9m2RYSRwNZRFplRPmY54HYckigD5VwPfHrijqO1aXieyg03xLq1haGX7Na3csERmxvKo5UbscbsAZxxms3r3zx+VAAfqfb6Ud+S2Ox9qD9AM8jmrmkWbX+pW9tGhZpGzhQTwMk8DnoKAPRvCTzaT4VNlcJmK8PnshQuOQOeOQcAVg6xcQXUvLqqgcbl5AHbIrrLqSQ6Z8xhaNOQVXOPqBz/X8q8+1OWW8V8suF/5ZqVPHrnFAGVdbXlbYMBTnLEnP+cVWbB6Ek8cmnmMZ52geuRn8iaks7Wa9uktrdfMml+6AepwT/jQ3bVlRjKclGKu2V9x55JJ70pYnPLdyOfzqxfWV1ZSFLyB4W6jcuM/Q96rDk9sn2pJp6oJwlB8s1Zh7DkdiaMn3B7ewpcEnkZ4703jHWmST3VzcXk5muriWeYqFMkrliQBgDJ54AAqH14HSj34P6UYHTNAbB17D86PwHPPX9KOvU8+9HbsBQAdu3HPWjHsOOOtH4Ljrij6447UAKFLcjaP+BAUUbQc5dQRx/nFFAHUfFj/AJKn4y/7DV7/AOj3rlK6v4sf8lT8Zf8AYavf/R71ylABRRRQAV0fhfxrrvheF49CuoLYs5kEptIZJUYjBKSOhZDgD7pFc5RQA53aR2eRizsSWZjkk+pptFFABRRRQAUUUUASQuI5FZo1kUHlGzg/XBB/Wrv262HB0qzGevzTdP8Av5WdTugI6j1Hek4pmkKsoKyt80n+aL/262xzpdl9N03/AMcoN9b5OdKss98tN/8AHKz+O57dhS9s8UuRf02X9Zn2X/gMf8i/9utgMf2VZc/7U3/xyur8Cxi4uLi8i061haIbVK+Yd2R8w+ZiBwR271wuD0AJ7HvzXsGhuNP0aDT47RXeNPnlhID7j1II59ev+NHIv6bD6zPsv/AY/wCRX1RV+zO7CFjGDhGkkT+tefXOowMzKNNtDjsWl/Ho9dNqbajCZWwWjwThz5UmPTjriuImffI+di7upyT+tHIv6bD6zPsv/AY/5Ftr6AHnSbIDBxuaY57f360fDur2drrNvPNY2tvEC26RDKWX5SOAWI7+lc6SR1wR1xS5IIK43DuueKmVNSTT/M1o46pRqRqxSvFp/CunyO+1nxtbPE0VrY/aEP8AFcL8h/4D3/SuGnkaWZ5fLSPJOVQbVU+w7UxR5gAGxTnH1pWhlQBnVwOmcdqVKjCkvdNMfmmIzCXNXd7baWsRsMcN1owc4wSx4wfWnMu1BnOe6kHimkjH/wBetTzyazuGtZ1mURuwBGJIlkHII5DAg9fT3GCM1Cepzj0xUsO1SdwBP8ORnP4UtwirgqfvDkfj/n8qAITwec56EUHjOcA9MYoGfu4/D1NHbocf1oAM854556UfiOOelHfqPXpR3xnOOmB1oAQ+mRxRSt2647Z9KKAOp+LH/JU/GX/Yavf/AEe9cpXV/Fj/AJKn4y/7DV7/AOj3rlKACiiigAooooAK2/CGiQ+Idaj06fVbPSvNGI5rtXKM5IAT5FY5OfTHFYlW9JvP7P1WzvdnmfZ5km2Zxu2sDjPbpQB3XiH4Ta3Ya/caLoc0PiPUbP8A4/YdMjkY2pyAA25RnOe2ehzWXP8AD/W2u9Ls9Osry6vr20a7eJoPLESq7Kx3FsFAV5c4HatXWPiX/aOo+PboaV5X/CVIibftOfsu2RX67Bvztx/D1qxYfFRYLPT7G50QXGnR6E2hXcQuyjzxmUyeYjhf3bA44IYeuewBy934D8T2l5bWs+j3Cz3NyLOFQVYSTFVcKpBwcq6kEcYIoHgTxN/Ys2rNpMyWEQkLSuyqSIyQ5VSdzBSCCQCBg12/hz4saLokNjbxeDWltNM1RNU05W1V98LiNEYO2z58lN2cAAnGMcVBN8W45fBWo6DLoP2g3aTqj3d0s8VuZZC++NDHvV1zxiQLnnbQBzzfDPxTaXtjFq+j3tlBcX0Vg0nliRo5JCAoKA5yc8ZwD0BrT8I/CXXPEmuy20cclppSXFzbf2hcRhRvhRmICFgSflCnGdpPPSuz8dfGHRrfxxqd34S01ru1u9YsNSu72W4dfti2pV0jSNowYfmyCTuJ+nFZWlfGe2trzT72/wDDJubvTbnUZrF49QMSxpeFy6OvlncQXOG4+negDxsnrySc5z60Y+gxwTRzjtjHT9KCPQH296AN7wNpr6p4ltIFSNtu6XEmNpCgnkHryMV7lZX+kxW4sfEHh9ZlY4Vg7Kygf3GB2+h5H5V558NfD07aVJqcVxEjSvt8o/fCDoRkeueeeBXXym3s0ZZ3VVcfJKV3xn64P06igDi/HsFhDcbdNurtVfOIpcMNv1z/AI9K8+kZnJjQ5XOB6cV1PiBBcSNFbNbSJk7fLOFH5H/69ci6lSQVAPoOcUALtdcjaQR970I/yP0pu0k4VSM+ozU6pKYc4Cpn7xzgdv8AP41e0uwSWRWlXaueG3AD9T/jQBNBp5fTlk8mJWIzuJxxz71lykKcTbZH6cZOPxzXXXZtYgscynaowrKAVP8AOubv7Z5rwi1gkYegU0AZ7Aj5thC5xz60mOMgksfT0xUksMkLBZQUYDp3/KmIN7heg56DJoAtmNEg4Uq7f3sfoPpVmOJX0iUJbLJKMOZCCdoXOcEH065BHHHNJHalFUKWkOM4Vew78/5/nXfaHpdnaaGb7VYpyjphIw2zcfQnqPwoA8rxgdDml9eelTXqxpdzCEYi3nZ3+XPFQ+meR6Z6UAHbjNH05B4HrR2Gfw5pOP8APagBQA2TuVfbmikP0xRQB1XxY/5Kn4y/7DV7/wCj3rlK6v4sf8lT8Zf9hq9/9HvXKUAFFFFABRRRQAV1vws0rSNe8cafo+vs8drqG61jlV9vlTMpETe437Rj3rkqKAPoPQvhl4ePi7VtJk086l/YNhZpqUaXMjSPdyf65okTGUUnaSWAXGTnNaWpeE/DOjaYvh3U0mOgr49lsWkMgWSON7OMKS+OiswJ9ga+aqKAPoPT/hb4WtPGU3hq/Ml7rWl6Otzc2sc7D7XduwOxQvzEJGynapyT9DXlfxW0XT/D/ji+sNHt721sVWN0t70YliLIrFWzzwScZwcYzzXIUUAXLe6hiiCvYW0zf35GkB/8dcD9Kl+2WpGW0u3H+7JLj9WNZ1KfqOeeBU8qNo15RVkl/wCAr/Iv/a7P/oGwf9/JP8afHPZzSKi6Yu5uAElf/E1nHOTkY9eO9aOhRyPqKsu7cmW64OaORf02P6zPsv8AwGP+R6H4Tv7XT9qweXAhwNsgDoeO5GfWt3XkZtOmnWNHCglfKnyM9euDt61ydtqjpCWmsVjmXJ3HJyPcY56+lM1XW7O809xDE8UuMNtY4z/umjkX9Nh9Zn2X/gMf8jnrnUIBL89lLG/dxchW/ReaspPod5EGntpVb1Eo3fTpXMyttk4YHHH3cevYU3JYZ9OvHA98Uci/psPrM+y/8Bj/AJHpvhG0sLZLxoEkEThcmdwwI546AD9e1Q6q+gRMwhIjmPGYV+X8R0x9K4rT78264Yg+g3EY/XpTv7RxcLJEgBz0Zwf61j9X99zuz1HnTeEjhHSi7X1a7u+i0sdVaaHHIjTXUpMbDJbZu/HIB9K5jU1FleNHZTNjHzYJJP4YrqNOkXULOM+dBGpHKyM2B9Pl/rWbrdrCNsJ8pye8TYH4D0roPEOZlVXYFBIz5/ufp+lRIzE5BKr/ABFeP5VsPZJZoxuEnmU90j49hnt/9anWHhnU9W3S2Nm/2Zf4iQoH4/56UAV7bUE3osxwkfOAuAT+B5qfXNel1FUi8x2jUYUFsKPwqDUNNOmyPHOYZZQcfu3LAYrKbkk/Kep6mgB2Y/KICt5uc53DaB6YxnPTnP4Uw8knr6mgdQMAnHbvR0GcHHSgA7njHcjPagH37c5/lR2+h696M5PqeufWgA4HXJ+hopyeZj93vx7ZooA6f4sf8lT8Zf8AYavf/R71yldX8WP+Sp+Mv+w1e/8Ao965SgAooooAKKsm1IshcebH9/b5fO7oOemMc+ua6O88D39tqF5Yre6dLdWljHfTIJWjCq5jCpukVVLkSocA4PQEtgEA5Oiupk8D6pDFfm6lsYZbSza/MQnEplhWTymKNHuTIcFSCwOQa5agAooooAKKKKACnHvuJJzzzTad0wRwexHf3oAkttnnxeZ5ezcN3mbtoGe+3nHrjn0rsbKDTBNJJp+4iQb3XYQkZ/uoHYsydCC2GwcHONx4tFJdQMAnoT0Nb2nw3MaKyKJABwnmY/nj2oA3bveLd/Jik5HB3EjP5/59q5e8ubp2ZZ3BJ9OGI/qa1/t13a5ESSGLJLRsd35etYuoTfapCYjJyMsrfz460AUmbdwG3dgCMf5700EZBJ3DqwJ7005HUYPTkUqkg8cHigBwV8naOc/j/n/CmsjKBuVgvuMZ9aeJ3AIDY79KZ5jZ3B2DZz1oAkV3jfMTFST0Rv0qW2u5o33idwwI5POfY5qsPu44x6nrQrKAcqCe1AHaaZdtf2myaRgw+XKoP04PP5fhUNxqF5pMLKs5lic/dbjB9+4rH0zU2tExGXQlh8wOc+xGK0tbvZb21WVSSiA5Jjx+WeaAMq6uLm5JaQLGv90E5/Ic/nWYy7GwRyOeavWgkkLKWZR6IB/LvT5dMn2bo0fJGenX/OaAM3tjjHrWrqCaWmm266fN5tztV55JVdXLFfmjRRldqnPzE5brx0qj9knxnym6gY9aZNBNCSJY2UgfxDpQBH36j06UA547emaD06/QdeKM++T059KAEPtRS4B7gUUAdV8WBj4p+Ms5H/E5ve3/AE3fFcrt7c56Yx3rqvixx8U/GWQf+Qze/wDo965XHbBz0/GgAxnpkj6fnU9vAXfiNpMc7R6e9Nt7d55Aqq3OMn0Hr9K29KRBczTRL5lrZxvLMJP9WcA+WDyMguVGOvJ6800ruwpPlV2SabqgstPvbSK8EMd1HtlXaG8wKdwUtg9SO2OSMnGTSeKfFl54gu47owW9lMLZLWVrMNGbhEKlTJ8xDEFV/wC+V9BiKTXbPeXg8OaPFIOY3JuH2HsdrylDjjhlIPcEcVD4ksI7bWJRA/8AokiiaGVgAJVPXbtUAjduXgYG0jtVyjpe97GcZe9Zq1/T9DSbx1q00Ws/bRDfXOqQm2e6unlklhiL7/LjJfCru5wQa5Tjn/GpHjKjnaCeMH+dMH0Hr9azNQ49D19aMD+nWjt0FJ26DmgA4/T1peMcfzoPpgZo49MfSgA/3ePxo9cHg9s0Hqc5J7/Wg9W3Hn8+aAJLc4kzhcY5BOBg8etbMM8sEWxYcxY4w/H6/wCfescbvL+VcMOSQP8AD8qfDI4BRFf8Mggf1/KgDYDicN5h2LjoR/I59v0rLn8pXzHJI5Jzhjnd9CO9aFjcR5Ali3ZznncP/rfWk1OCyCMUzG2OnPX1oAxSxJ6j8OKMAcEYPTJPShsA4DFgOnGOKTpkc+5HPFAAc9Ome1BJ9RjH5UDjsDjnr1o7fywKAAYz1/MdqASCCpwRyDnnNB7579cDoaPqPb0oAv6bcrHKPMLBeMYYj8OOasXr2zJ5kRZQevzZB/P/AD/XOhQMMnknjGD/ACFWHt5CgZkiQDjAwGx9M0AXPD2ny3s+Io5CvGNuCfxPb8Pauot7KSOcRS204x2HK/iT/UetS+Cbdkt2dzLEhA5XC55Prk+vTmjxJqS2h22fmyOeNxct+O49PrQAkt3BGNsqwxr93cHDH6bucZ/z6Vhahb21wX8l08xxxlwOT65IA+tYdzezSzM0zZ56E5IpiXJB2oEAPfsPXrk0AVTwSMAH+XtQDwOT6fhSyDDYyG9WFIfU89yfWgBD25zRQ3XnOe+aKAOv+LEEv/Cy/GVx5Mnkf25exmTadu7znOM9M45xXM2cHnOeqgDI4JJ+ldP8VJpF+J3jWASssMmtXZdA3DETSYJGecZPXpk1l6YRuMUW0FjhScnB7kHqB0/+tQBZhiVbO9uZR5e3C4YbQcn/ADwOlUrkfYdCgtwJY579vtEgbhfJHEQHfJPmMc8YEZHeutvdL/tGawsLaYGKZi2DGCVUAksMEA4UEnnt1NcPq14t/qM1xHEYLcnEUO7f5MY4VAT1wMDPU4zVrSLf9ef9eZD1ko/P/L+vIp8Y6/pXT2V1b6hotlDdTMs2mkwwxMP3TxuzyMSCfv72A46rjj5c1zkcRd1AOcnBI5/L/PpXcafLb6RpK2sLQ/bLv91L5jZOHIHAyM44POAOTnPFKLtp3Ccb69jkbiCeaWSU7miyNz42rj3+n0qoI3+YqudvJyOlPkneRQn8IPC9T+dWbCPc0YKlwzYxng+np7/pUllYWlz9ia7FvIbVXETT7CUDkEhd3TdgE468H0qHt29K6PxhaT2U8Fv5k/2RMvBbySllg3kMQAeFBJBx16Z5rnB+AHQnFAAQQCOKDwDg4H86Ov1o6+g70ABGPp27UDIYDGGH4UHuSBn8qs2UUblhNlV+7nng/wCeKAIkVSgKttPU9+/WkRslRgEjoTn+lT3CLCx2yLMhx15/l+NV8k/K3C/TJAoA3NIjYjzVi3hvvANggY/DP/66NYeFh92aI9BuGB+VZ9tPIso2tsIOCycHP0rZnWaS0JE+8Y58xPp3PSgDmTwQAScDjHp1pOwJGB6+tSTBgxDkc+mDg+n0qP3zk/yoADz39+RXUeGtEstesZY98lvfwn733g6nuQfTpxjtXLngdPzPQ1o6BqT6RqsV2oJQfK6j+NTwf8fqKzqqTi+R6ndl1WhTxEfrMbwej9H1+W+hPrvh690YB7lY2gY7VkRuCeT0PP6Vj47EY7enNdLq2tJ4ilMdyVtQpP2ZicqM44f6/wB7t/LnriGS2meKZNkiEqQaVKUmrT3KzGlQjVc8Jd0+l/608r9Cxa28rAbTEATyHwf6HFa2mRtPcxpNMiqrDAAClvfnj8658NgdTtzxx1rqvCupTwv+4tomOQS+3JH0yK1PPPS9N+zWuk7iscLY4UESM3/fI46Vx+sXQm895FVY+oCLsY8nqTS+IdYupbURSR5xnLEnH5Zx+HH9a4SS6mV3G8buucZ7enbpQBBdMGncKwCZ4Gcge9Q9u3PHSldmb7zEmnxKrNliVUHjOP60AEUEs5k8qJ3KLvbauQq92PoORzUY9uD0rU0HVjoeqxXsFtZ3jIGBivIfMjbIxyODx6jH5cVnzymeeWV9oaRixCIEXk54UYCj2AwKdlbzJu+a1tCL0op6hzkoGxn+HNFIo634pFf+Fo+NAwJ/4nN4OP8Aru/+eaoaVCyxRPEV+dtoYn7ue4Hvx6VsfEjym+LPjBXBQ/2xeDdjIz578/lWbBGq3aNE6RRuSQXJA6dT6E568UAdd4j0+3tfAxvIDi8wLclgh4cgkhgc5wHB4IwTXlm0jqCo7ZFdz4+1K6+xafpjLMiW67pY5CpxO2C3QA5HC4OcY/PheMcDp361c1b3exnTbacu/wCX9ak9tcMk8b5yydCT/XjjrRe3U15O01zK8khA5kJY+wyadpzFb2AsNyq4JUrkYJ549K7nVrrR9P8ALmi0+0nLJk7w2VOcZC4AHbg8c1BoVE8KXOpumsQrax6beI0yYXasbbiDFgAcgjGQMYKnjdiqw01dMM0knlZibaHK4yfqT/Kt/TtebU9EdrPUIINXgMjm3aBVIh6bIm+6wyQx+7gbyA2CTzus/wBoAeVe30E07AMywyDCgkcccE8+nTvWlRWd+5lSldNdtCveTzXSPI4L5z5jnnaD2BP9fT0rnW5Y4A54610d9eRRWawRkYRcBCcbT64H9etYDwtw3AV/unHUeuO1ZmpD9f5Uo9eD3Iqea0uIrWC5lglW2nLCKUoQkhXG4K3Q4yM46ZHTNQE8k5JPXkd6AAAkgAEk9MetdWbCS0sIoGs0dwM+YPlbceuc9cdK5yyheWfEfl70+bDHg4/HmtxdU1K3DI6krjG1+QfoaAMidJWkcvEQ46qVwT/nr37U21VPN8tyvf6fkf8AP41Pe6jNM+2TCjPIbDL6dv6VTXceVjDJ0+7z9aAOhtXQOqMyR9AHxkAds4x+lbi6X58BkikO7H34TnH1Gc/hXG2imQD90Co6GMk4P0yf6VpWvmRuC0jIh4DKx29+uOlAFHUYHEzqxAbO35wAT+v+fftmuhRSGyG44yOfetjVIbkyh2xNGB97AOP5H0/OsqVWDfdOF4O1SPrnPT/69AEPXpz+FA+gPtT9jNyEcgHBPf6flThEucGRM8dASaAIhj1/StK2uYruFLXUHKMo2w3HUxj+63qv6j6cVSeBh2yO2Bj/AD0/WocjjP40mrmtKq6b01T3XRk91bS2k7RXClHA7dx2IPcH1qaxuXgc/vPLxx3H8vxqW1uopoBZ6ju8oD91NjLQn+q+34iq93bTWU3kyqCSMqR8yuD0YHv/AJ+lJPo9yqlJW9pT1j+K8n+j6+t0rV9eeagH2meQAZwMgfr7/wA6zTswMEn17UEgnnGOuFH6Uh6fNnPr/KqMAzkcntijHJzkevHSg55J6+/fNH4igA5JHcn2zzU0dtPLay3EcUr28JVZJAhKxlidoJ7ZwcfQ1CBzgkDHpzUsdzPHbTQRzSrbzFTLErkK5XO0kd8ZOM9M01bqJ36EQAbksq+xzRSHrRSGdj8VE3fFPxiQQCNZvSfb9++Pp+dY+l332PUoJL2E3FujAyW4bZv9skH0HY/StT4rOyfFTxkUOP8Aic3n/o96577WJAftCB8nIIODx2oTtqJq6sdjPZW3iCKT7PqzrK581l1CJixJ5wJE37yM8swjzkHHJAwT4T1mQE2dqmobTgrp9xHeMo/2hEzFR15IFafhm50yW4W3ZGBfgBWwSeyjOD+td+/wxtNXmjaTW4IZXXcy6hFLAy+oDKH/ADb3rTmi91/X4mfJOOkZfev8rHlieEfEqsrDw7rPHP8Ax5Sf/E1oaloWuXOz+0YIrNwBtF/Olo7j2EzKWx6jivQX+DZtopbiKTTZ4ozgS/8ACQQGNsYyMCMEnr3HSuE1fwxFbXjpLewlRyWRvM/ANgA9P1PU0Xh2f3/8ALVO6+7/AIJV0e20fTLoSXurrqNs+EltNOSZTMu4Ha7SCPAyFIxu5A4HWoLSwjQ5jmM0+3DsV2oM9QS3UdunXpmptOfSbJy7zDd0DOM7cH0AJ7d/8KTxNr1nqO02/wBuuJHQebJclUAbkbQqZ4HHORnnjuVKSktrDjFxe97/ANdERX0tlbRD7MUeQnDkr/F9euPxGe44rGubppp2dtuTxwM7R047du1QO7SH5iSAPy+lNB9yM8HHpUGhoS65qs+lx6ZPqt8+nJjZavcOYVxzwmcDH0rPPPP+RQScEnHPtQOowOew60AXLJ1jjbDDJbOGO3IHQg/nSySbj8u9VPQ7xjP8qpDr8p7fSnRyMhyueP5UAWWbCAyMeOAWGf16imSSOE4wf9pWzj/OKYJDk9Qcfw4IP19e/WiMLJ8p2Dp85OAPx/z/AIgE0FyS4aRPMPqDhvwPXvWrHPuBUySgDgrKue/PJ/xrKFpIOWiDqecq36Yq7YhsjyeOM7TKP5HjFACXKW5y6ygkdxx9Ohx3rNZ2xlXY4GeT/wDX/wA8131i9tJxdBUYDGXgzxjnkD/Oapaxo0Myb7aZZWX5vkC4P6/zoA4rJyDnJ6DmnCRgc/L68AU+S3eMkOApHXPOKh6YJA9ee9AD2dn4woyP7o/wppDZIYHJPI7k0nY88elKELD5QWOO3NACAEgDBOen1q/ZXcRhFpfAtak/K/VoSerL7eo7/XmqBXacNwc4NTLGpXo3ockf1pNXNKdSVN3j/wAP6j760ezkAZlkjcbo5E+7IPUf54qrwPQ4P51q2s4gja2vMvZuclMDKHpvQ+v8+/aq19ZvatG6OJbeTmGZeA319CO4PSknbRmlSnGUfaUtuq7f8Dz+T86nToaBjPXHoSKARj+nY07jp745OR9ao5xvpnjPftQM8dPQUZ64wM0HgkYx6+1ACHtxjNFKu3uWH0GaKAOq+LB/4un4yxx/xOb0cf8AXd65XHJyp46j0rqvixx8UvGXT/kM3n/o965QYzzQAv40EdTj8ugo5HftScde1ABjjPOKXucjBz+XtSkZPPXODz3pO3XjvQADk5POOtLzjp17k96Q8k5BJHU5owM8/kKAA9fmz2/Kj6nPfB70Y4+vrQcen0oABx3OfajjHb60pz/F15z65pOe4PTqe1ABnjsKPc8/U/pRk9c8jpRjnGDnpjvmgBDxkHg9xSn8OaTsaXPpgfSgBVZlzsYr2ODjNWodRuIWVt24DBww+99SOf1qp9celJ9DzQBvweJZowwaGPB+6EZlC/Xk1I/iKKVTutmRz/EsmcH8RXOnIJzgHvxR0yM89/SgC3d3X2nAdXLepOSaqDAbg49DnpR2PpSDvyQDQAozx+fAzUz206RJI8EoiYjDFCAfTBx3qHselfVGt+K9DvvhV/YeneI7V9V/4Quwi+yXd/H9iJUnzFVc4W7XA4JzynHBNAHy9d2dzYzeTe28ttKVDbJkKtggEHB5wQQQe9SC3uVsheraSizMhiE4Vtm/GSu7puxg49Oa+goNL8LanrXiH+w49A1LVBaaVHaC+uBJb7WjAuNhLbTKCMbc7hztGcitTUr7wn4bu5vDctn4dk04+O/Jlsr5wRa2j28KPMF3DaB8w3tkAg0AfMDOXwWI655x1qzZXjQI8EkYmt5PvRE9T2YHsw9fwr1/4oajo1z8KtG03QZNAeLStU1CAok4NzHGZwYmjBbLK6jLMAQcDkVf8A6f4Jf4WuNaufDk97Pp96+ZZYYLq2uF3GJfmbzHY4GCoC44wSeU0noy4VJU3zRep4Ln8RViWzuYbWC5lt5Utp9whmZCElKnDbSRg4yM46V9E6vq3hbWU0fUdUj8KXVpa+CXEMBuQsn2+KJcW7IJA6gHhRwTk4J7Yfh6XwXrNr4GGsHQ7I3n9si6tzcFYLSRgv2fepZjGufuk9cZycUyDws8k57dh2ozx1yPQ17zZ6Z4I0LTLc3j+FtU1G08MXszj7WssU1+tynlKdrAs+wkBR1GcZHNRfEeTwRdeGfFkej2nhu2u7UaXc6fJYSjzZZJlP2lF+c5VD1RRhe/PNAHhmV/jDEnnIaikDFeBgj3UGigDrvihGJfiz4uRpI4g2tXnzSE7R+/frjJrBl0uW3Qm7kjgZZmhAfJG5cbugP94e3Wtr4sf8lT8Zdh/bN51/67vVXxddRXEtt5BG2VDcNz0Z+31+UfnUSb5kkYVJTVSMVs7/gVDoN+XeOFEmkjIWVYnDFCefm/x6cVa8NaZaXOvwW91LDcIWZWhiLkthW6EDnkA9fzrAFdB4Bz/wAJZY45AD/h8jU0n1ZSjPrL8P8Ahylc6JdWdv5195Vsu7aBI+WJxnG1ckcc81HDpplt5Zo7q1ZIceZ8zAqD3wRzzgcZ6iqA5POTnsOpoHbHPHSi0urBRnbWWvp/X5mqNCnKLKssLWhUsbpdxjTHGCcZBz2x3pLLSTcXFuHuI/s0pceahzt2gs2QcEcc9Oc1lnHQfhXRaNPCvhvUld1WaLLx5PJ3AKcVE3KK3Mazq043Tv0276f5f5GXHp4mnEMN1bvJIQIgCw3k8AdODn1IqzLoxtCjajcxwwuf4MszEZyFAGODwckDPesj0z0/LIoH0z34q2n3NnCbektPT+vyN+XwxcJJIVurP7OgyJnfAYYJ9+QOfyrJa2hBP+m2569Ffn0/h7//AK6re/FHAzzntx3oSl1YoQqL45X+Vi9badLdB1tpIpplXcIYwS7Y9OMH16/rUj6RKtytq80CXZUEQksGyRkKeMBugxnqazQOf5n0qzpkqwajayyY2JKjH2AYGk+bowmppNp/h/X9dSV9NMUUElzcQQecpZVbeSADjJwp64qwdEm53XNoAUEv+swNh6N06exwfaneK7iGfV3FpIHtokWOMqcjhRnH45rG+g/WlHmkk7kU/aVIKd7X8jRt9Klu45Gs5YrmRACYow24jOMgFR606bR54Y3luJYI40cxF2fdhh1GFycj6YrNPIJwfrQMfT8elVaXc05Z3+LT0/r8i/Jp3lQxSPd2wSUbl+ZiW55425GPfr2zUx0O4WMzSNEloEVhcMWEbZ6AHHJ9sdvxrK6jJ49/Wjgjp+tFn3Bwn0l+BrtoNyJ0j8yBg0TymQMSihWKnJx6jHGe1Ur20a1WJxLDKkq7keInoCQRggEflW3p9zEvg+8DyL5ys0McecEhyh/Ho35VzXHGc/Wpg5Nu/QyoSqTcuZ7O22/9aB+ZUc9MGgjoTnp1o9Mjp70dPrWh1Glouv6xoTzPoerX+mNOAsps7l4S69g20jI+tUJZZJ5nkmcySyMWZ3OSWJyST60z2Az+FAyeMfgD1NAB26HFKc8kk89T60mOvfA7UdB79KAE47UvfkFc/wAqD7nJ6UdDxj1BNABn154/KgnPfryaOgPPPejnuMD0PbNACE/l29qKCc88575ooA+j/EOm/ADXtf1PV7zxxr6XOoXMt1KsVs4RWkcuQubUnGScZJOO9UP+EY/Z5yceO/Egz2ED/wDyLXz9RQB9Af8ACMfs9Hr478S/9+H/APkWpLfw9+z9bTLLb/EDxRFKucOkUisOMcEWtfPdFAH0B/wjH7PWMf8ACd+Jcf8AXB//AJFo/wCEY/Z5xj/hO/En/fh//kWvn+igD6APhj9nk5/4rrxJk/8ATB//AJFo/wCEX/Z5/wCh78Sf9+H/APkWvn+igD6A/wCEY/Z6z/yPfiT/AL8P/wDItB8Mfs84x/wnfiT/AL8P/wDItfP9FAH0B/wjH7PQ6eO/Ev8A34f/AORaX/hGP2eh08d+JB9IH/8AkWvn6igD6A/4Rf8AZ5/6HrxJ/wB+H/8AkWl/4Rj9nnPPjrxJj08h/wD5Fr5+p2R2+g4oA9//AOEY/Z5xj/hO/En/AH4f/wCRaD4Y/Z55/wCK78SAHt5D/wDyLXgGR6+3TtRkYx/SgD34+GP2eicnx34lJ/64P/8AItB8Mfs9E5PjvxKT/wBcH/8AkWvAc85/HoOtGQOn8qAPfv8AhF/2ef8AoevEn/fh/wD5Fpf+EY/Z5/6HrxJ/34f/AORa8AyOmeOnTtV3S4IZ5Ha6JESLkhR1PYde/NAHuX/CMfs8kc+O/Eh9/If/AORaP+EY/Z64/wCK78ScesD/APyLXjeo2diTGbVjA7fMUc7sDnn2/lWRIiISBIDjP8PX6UAe9/8ACMfs8jH/ABXfiTjn/j3f/wCRaT/hGP2ecY/4TvxJ/wB+H/8AkWvA9hzjvjGMDv61cOnkx745UdTgBcgMfoM/rQB7gfDH7PROT478S5/64P8A/ItH/CL/ALPP/Q9+JP8Avw//AMi14dqMMEMm2EsQPvHg8/5NUs8g/j0HWgD34+F/2ef+h68Sf9+H/wDkWj/hGP2eR/zPfiT/AL8P/wDIteAZ/l6UpIx/9agD37/hGP2ecY/4TvxJ/wB+H/8AkWj/AIRj9nnOf+E78Sf9+H/+Ra8BOCevH0oB79856CgD34eGP2ecY/4TvxLj/rg//wAi0v8AwjH7PIHHjvxIPfyH/wDkWvn/ADwP8KXI/T0oA9+Phj9nk9fHfiX/AL8P/wDItFeAHr7fSigBK9PtJ7DRPhpoGoHQNL1K5vLqaGVrqEs7KGOArAgg9u9eYV0+i+O/Eei6ZFp+maiIbSIsUTyImKljkkMyk9/WuXFUp1VFQ6O+7V9H1R04arGm25dV2T6rudn4q8KWelDxd/Zp+z28Vla3X2aSNZGiMjnMe5vmXHtzg4NUNR+H9jF4Y1G9jmvrXUbG3S4e3u3gJZTjPyIxdOvG4VxX/CRaqU1RHvZJBqYUXZkAdpdpyMkjIwfTFaWoeO/EOoWtxBdXsbJcwiCdhbRB5lHTc+3cTwOc1zRw+KhZKa3V/uXl5P8AA6HXw0rtxfW33v8A4B1t94A0jTLexvEnv9Rs/Ot1lvLfyXt5A7KCAA29euBng+vSm6/4S8PT+LvEAtpb600/SI3nvIo4kz1UKkPzdDk8tjFcjqfjbXdRtHt57mJEkdZJTBbxxNKynKl2VQWwefrUs3j3xBLqa6g11CLry2ikZbaMCZWxkSDbh87R19OMVMcPi93PXXr6eXr6fgOVfC7KOmnT18/T+tTr/D3hfTbO6kvbRmvNN1DQbu5gW8iXzInTAOQMjIPRh61Wg+HGnJo9s1/qpt7+6sReJI00CwoWGVjKs4kOem4DGTXI3HjPXZ757tr0LK1q1kFSFFRYW6oq4wo9wM+9SWfjfXbSwgtI7mF47dPLgea2jkkhX0V2UkD8eKbw+LWsZq//AA/l/wAOCr4bZxdv+G8/+GOZooor1DzQooooAWlJ75xxwB/Km04A8bQc54IoAMnvntx7f5xRnjkn6fyoAPbPI/SgDrjOO/0oAXLbgMtuz+tIM9s5xRzjvjvRhumD1xjHegAyccEkY5/z9a6nwuvk2dx5roqXAABdSeBnH0PWuZhjMsqIMnccf410FzdG2git4/MeE/JkgAfoeOn6UARajbQBT5MqSyfeZWyOOnGcZ6VjzKwlO3DHPOPzxU88mGKEYDDcAzdD/nPWpbH7Ot1F9pV9vVvLIGVP6fnxxQAyws2uJVjjy4zklOcjjPpjr/OtCfURZwLbwRKmOCd2c9uvXP0qxqWqxWfmwWIOwgDDBeOOvT3rnWmMh53H2H05oAmv7sXTDEaKF9Byfxx9aqduc7eM96Vsn72WI9+lT3l3Pd+T58nmCCMQxnaBhBnA4+p680xalfJ4JLdSc+9AOB1IowWx1OeBRyTkE565pDDJ75x6e1H+9nP+f/rUAEcjOPXHbpRjHXIoAXLZxlt2envSZ4ABOf5GgA8gA+hGP0o5xxnB/U0AIe3JIopwZkHyswB564ooAZRRRQAUVNZw/aLuCEttEjqmfTJxXtfjv4I2vhhofK1XUJn/ALXg0sQ3dmtr9s8wA77d97BgM4JIwDn05APDqK9Kh+EWuahq19BYtZ2kS6tPpVnHf3SrLcyxsQypgYYqAMtwM9PSrk3wgurvwromo6LfWj391YXN5PZXN0iSv5MjqwhTGWAVcnP50AeU0V2nxG8Ct4LTQ3OrWWoDU7CG92wsN0Rdc4wCcpzw/G7ngVJN8L/EscMkq28EiBLJ4ikwP2j7WcQCP+8SQc+mDmgDh6K9Muvgr4sg1LTbJV0+aS+mmtleO5GyOaKMyPG7EAA7VJyMg461a0f4LaleSSm71zRobRtIuNUtruC5WeGfyThk3ZG0A8M3IX3oA8por0jQvhVqdxqHh/7fLYvaau6/Z4rfUYVuJkLMu5FbJxlT82CKzrX4d6hJpkGp3l5pthaXLSm1hu7tUnukiYhzGuOSCCBnG48DNAHEjrx1oA7dz7161qPwV1e58X69p3h2SJtN0+//ALOhuL6UIZ5ioYRjaPvYI5wByOea8svbWaxvJ7S7jaO4gkaKWNsZR1OCD9CKAISPwPXn0owM98dcE0ccf49qTj07etAC7ecYOemO+aMemTScYP8AjS4zwAc9OtAGtoFukkszyByAuE28HJPXqOOtO1aBrS4jCjDsOVUHk56c/wBKbo06WjkhA7upBVgDxx+NbOh+HpNbN4181xblChiYrwc5z164wOhqJ1I01zSOrCYOtjKipUVdv9Ffc5WQbGztYHIPzZBpkIBkUFgvI5zjFdPrPhCfTImnS9tjCO8rbCfbHQ/TNcyiyNjarsMYIHf/ADxRCpGorxYYvBV8HP2dePKxxKI2QOCOmM/z/wA/1awMnzZLMSB/k/l+dXV0q6MSySGKMHj97IF/DmmSWMiId0sLgDtKDjr/AFz+tWcpTwoPOR68Z4pXwCV6j6c9KAxToSPp1xx3po6jGd3bFAB1z06fSgAc9cevt9KuarenUb17j7NbW24IohtY9kYwoXIX1O3J9SSap8cHHHfBpvR6CTbV2GOOf0oxx0P1o4xz/OjH+c0hht/w9iaCOnUZ6Zo4/wAmjj0/XtQAuF53Fh6DGeKKQbQPmBJ9jRQA2iiigCW3laC4imQAtGwcA9Mg5r0rWPjV4j1mW4fU7PSbkPqUOqQK8UhFnNHtH7k+ZlVYKNyknOTjBOa8wooA9y8C/GPTLCSfUfFdg99qKavc6xaQW9ouyGSYAsElMwKAtnIKScAY5ribT4oazaXGjzRWunFtLs7qygDRuQyXBcuW+flh5hxjA6ZBrg6KAOk8VeLrvxNp2iW2oWdikulWiWMd1CjLLLCgwiyZYqdozggDrzmtS4+J3iKXwv4c0NZbeGHQbhLq0uI4yJi6MzR7ySQQm5towOveuHooA9Ol+Mutvr1nrC6Vosd/bySyllScrK0kTxMWUykDiRjhNozj6Vm6F8T9Y0bTdJ0+Ky0y4stPsrzT/KuInIuIbp98qyYcHr0K7ePWuDooA7eH4k6tBr3hfVYbPTUm8OxeTZxCN/LK7mYbxvyeXI4I4Apbf4h376NbaXe6Vomo/ZvOSyubyBjLaCVizBGDgcMxILhtp6Yrh6KAPXE+KXiD7ZrMl/8A8I7Nb6pefb5bWR5vLin2hSyGGQOMqACCxBwOK88v/sl1fXN3PfxiSeRpSLeFyqsTk43Y45rHFL6478Y61Nn3Oj2tNbQXzb/Ro0Nulr0e9l+qLH/7MaTz9OUfJYzNjvLcdfwCis/t0pffA69M0cvdh9Ya+GKXyT/O5f8At8C8x6baKP8AaLsf1bH6VLbapKZ4xstok3DOy1jzj64z+tZeOQML6dauWCy4YpGzRsMHHUdOn1o5Ih9aqr4Xb00/Kxq3+vXBkYRSTRxHoI3IGM9Sv9OKq6Tr99pbTtBJ5jyqFJly23HQjnr1rNnVBIQN+B7dO35VGpx3GPpmk6cWrNDhjMRTmqkZu62dyxfXt1fzGW8nkmJOMsen0HQU2zIFwnRT1DHPFQZ46846/wBK0tItXuJCyPEu0fL5q8VSSWiMJzlOTlN3bOi1i6ku9PjjIiWSMY3K5OePc/5/WuPc9AU57+//ANbitW+aa2gMKzxnnBVcE/gf8/rWQvK9VGBjLH+VMkfIcrhmAxxgEk4/l/Kou3oPelYbTgMrduBSDr6ntxmgA4PT9TRx1xwOx71b0qe1tr1Jb+z+22wVg0HmGPJKkKdw5GCQffGKqcg+/UHpTtoK+tg6ds0Y7Y5+vFA9cZHvR07A/jSGHbp+dHbpx6mgjHYccdaDx6Dt60AIevTFFHpRQAlFFFABRRRQAUUUUAe3zXOj3HwU07Vx4R8Oxalfao+jPPHBLujj8kESrmTiUE5ycjP8NLqPgTw7pOqeP9G0i6vZZ9F06RpptRtoGXd5sQXYcErgMcsNremBkV5Q1p4gSyNm1vqq2lvtvDAUkCR78BZdvQZ4Abv610ukeDfHGq+KYtLvYtV0q/1qKYmbVVngW5WOMysGYqS4wnoecfWgDuW+EOhnx9a+E0h8UJIszQy6rIsYtbk/ZJZh5Q2fKS0YABZ9y7jwQKp+HPhDp8lt4ZfxNJrGn3Go2F7d3Ns0LRmN4Z1jjUny2MSsGBLsrDkf3hXmpl8VGC0jMmueTaQC/tl3S7YYRwJkH8Kf7Y496sX8/jXS4bLVb+XxHZxShha3kzTxq4f5m8tzjO7qcHnrQB65H8E9Gi1FIL2DxE3na8mjpHaTwzGCN7aKUTu4jwVBkJPC/LjIU5qha/DLTb+y8L29zePNbR2ms3U32C3iS4vBa3DKEjYLl2YDI378DgccV5jF478QQ+F5tCh1CaO2mvXv5pkkdZpZHjEbB3DfMpCjg96bpSX7W9hPBr0kRtd32aOG4YPbliSwQFhtyc5x1z3qZSUdWbUaFSvLlpq7On+OmladpN54Oj0nTG02Kbw5bTyQyoqzFzJMC0pVV3SYABbAzivNDj3x0Az0rqNStbzUZlm1CTXdVlRNivIu8hck4B3OcZJ/M1nywwwZ/wCJPe8d7iQ8/kq/zqVVT2OiWAqQX7zT73+SZj5x9enFA68EelaBv0Q4i060jYdMhnI+u5jR/a92MeW8MQ6fu4ETH5CqvLojH2dKPxT+5f5tFOGCabiCJ5CeMIpY1qnTNUSCNVtZYgRn58IOeepx/kmqn9oX1ywWa9nK8Z3ytgD6ZqvL5jTMHJLk5G7Gefej3gvQXRv7l/mXm06USZuLi0B6YluVYj/vkk017K1jCl9RgAx/yyR3P6gCs8jDYOMH+VNBI5zz+dFn3D2lJfDD72/0seqQroa+HrGW+W2eLyVVXkjAZsADgdc8dBWHK2ku4ayhkt9vKlhuLD1GT0z71x9qxa4jy6DbjBk6D29O9dFfvKtkwdYACPkKbWz9CO9Y0qHs23ds9LMM5eMpxpqlGNktbXf39P61MLVZ1numKbsdOT1zz0FVBtIAx9Mn3pXWRiS4PPdv6U0cdeM46fzroPFBsZ67h7cUnQnJHpxzUrQyYB24Yjpnkj6VF6dc9ieKALWnxlplYqm31bp+VT65aS2lzG8q5WZQ4JXAOODj2q/ott9oISWQbRjkHbj8h/P9K2/FFtp0mgSSL9pkvLcp5brtWLDHDBgef7uMe+aaVxN2OEx2wc9+OlHY46Z/GkJ470vrg/TPpSGB+vTgYFHqM8dOO9B/EemfSjn0OcenbFACHOeRiinAhf4AQehOf8aKAGUUUUAFFFFABRRRQB6xd/FS0ufhzo+hTabPLqURtbbUrjzdi3VlbSSPFCCDuU/OAT/sj2x2DfG/w3DeaY1npepLbWepXV6I/Igj2Ry2kkIQbCNxDOCWcliM5PQD53ooA9Sj+KEUfwkj8NixkbXUX7D9uYgqbDzfO8o85zv+XGMbeK0Pin8V7HxnoN7b2sF/aTX88VzNatFbmFJEGMiQL5j8cDOMA85rx2igAooooAUdasR3lzF/qrmdP91yOfzquKXtyODSavuVGco6xdi+NY1IDBv7hgOzyFsfgaX+1rsn5jA//XW3jb9StZ+PQHnpx1pVG5gFXqQP8+lLkj2Nvrdf+d/ezo9MnZ41knsbZo3/AIkiC4HocY96TUWsIiqy6bCHbABV3UY+hbA71PcXtvZRLZ27tuRRHvx8smOuRnv/AIVXi0+S/ZWmuFBPAITKj29qORB9aqdbP1Sf5opPNZFAZbK5AY9Uuhg9+6mmbdMI3hb6Lv8Awvj09KvXWlPAzJcNv2gEPEwpthp8BAkKyTDGCqgKfryf/r80cofWJPeKfyS/Kwmj22mSXkf+k3TDP3XgUD8wx/lWj4hitWRIlvYYgMf61JR29lIq0ljZ2kRmR0hXAwJRlvboM1yWpzrPdFg4dezBSOPoTRyvv+Qe2h/z7X/k3/yRMNNznyr2xkGcZ37f/QgKF0m5J+T7NIT/AM87mJv0DVnY9Rz6dKDzk9fU+9Fpdw56L3g/k/8ANM39J8M3eoXhhkV4I9hYSlQVz6cHn86deeGrnTXLX0bG3GS0kXzLj+Y/HFR+GdSfR7qS5jtzMXiKbS20DLA5J/D/AD32F8U6jfOq74YEbjbEMt1985HvxWLdbn0tY9SmsqlhP3jkql3tr6X2X6jdDurG3XcsTKCcKoyc/j3qt4gv3urjbEAI9pU+wP69K3Y/Lh06SZ7mNvlyI0hBJPux4/CuI1a9e5nO8/KM4XHT8K6Dwyi3DEA7gPT0pvPQntU/lQfYfNNxi58zb5Hln7m3O7d068Y/GoM8f0ptWEncD9BnrxR16DAz1ox17+47UH35PUnNIYhopW689e5znNFADaKKKACiiigAooooAKKKKACiiigAooooAUUo/AA8c0gpevOO3agAxnp168dq2/Clj9qvjNIhaKEfgWPQc8epx7VjRlBIplBZAcsFO0sPQHBx+Veo+FrT7BaY0uQz290FmyeCNyg7CGGDt5XI7gkcGgDhrq4Md7JGq5UdcqB+fHfpV+LVUiQEQvC/Qsgyre5ArZ8R6dJDcPcfaVAOMwvb42n8efyrl5fOZ2jjEfmH+FPut6EA/wBKAKt/eSSzht0hA5ywq5DrkkVoIhaRlQOGB2kflj61lXKTRMVmQxtjngjP9PeoCOTkY56elAGxdeILyeExMVCcgoRn/wDVWQxBYkADvx/KkAIP3cEHHPr70KSCMNjH6e9ADy4YbTk56HPNM3Z5HBHTFLnI7c8YzQM8EZ9vb/PNAF23sbm4iymSvpvAwPXH41b0iC2Scfa3WIHqXIxVKEtMBl9ig+mB/Or2mwNJdIYo2l9SFwD+tAFnXbeCDbJaXDtHg4KBgB/n8q51jnnHXn3NbfiOV0uFTds2jBjB/wAOlYfTv+IoAOPSjPHYnH5UdQTj8u1bWs6XY6dpWmyw6rb319dp509vADttQRlVZsYZju5AxtKkEHINO3UV9bGLxjtR0HB59RQO2PXjI70c4HXHb60hiHtxgdqKKKAEopccdRRj3oASilx7ipoYQzjfuK56L1I9qACW3eO3hmPKS5x8p4wcdSMH8Ca6DUvA+t2C6hutvtD6csL3iWwaU26yRtIrOQMbdqnLA4GQCaZtgksWt/KtFlizK7TzFJNoU8KC233xjcTjHpWl4r8S6bNc6g/h2OaOLVJVuLqG6ix5UohkjbY4kO4MZ5WOVXB24GOKbQk+hk3vhHVrLRrnUrqAwx2kscFzDKrRywu67lDI4B5GDkZ6iufr0DxF4s0a98Pa3BY21wmoatdwTSKYvLhgjhVgqqTK7MTkHkDknsAK4EqB13Yz6dqQxtFOC84IOemMd6MZGefyoAbRTsfXp6UEdevHt2oAQe9B6Y49aX7vTv37EUDjoR2NADoUMk0cYydzABQCevtXpWg29t5SC3mZxFgFDwyHHTg5rjPDFr518JC+zy/utgn5vX8P8K9G0wSyLDJ5KXLr8vnRBXJx6gnNAFHXtM1i7hM1rKCoONpbP8jwPfGK55tLvlBluInM6dWi+dcf8Br1yFhPGYI4oYpcYZSGH5ocj0qjLpkyzs1qtsGPJEcm3J/3f60AeIX5kml/e5yvXAIx7kHFUyjIuWTGeOa77xDot7JdeYIdw5yuBuH5H+prlJ9Nu1lZWEgHULg/y70AZBGCeCD6Gl9/w6cVPJbyDjyXyO+OtR+WcklSQDjr0/GgBnTpx3HPIo65IHvx2qRRhyWQ+p46f54pzRq4Jjzn04/DvQA+MBmUMdkZxzu/oT6VsG/tbaJFgQOcYJKYB/HPP51iKJDwj5PdQTgfjTliLP8AMrMW993f1FABdzfaJN6r0HZABiq+e2eOnHpVi5hmRFMiuq4GAc/5/KoACzDaCT2HWgBD79fXNBx9P6U8wuudwKj/AGuOcVNYWVzqN9FZ2ULzXMzYWJByW5ppNuyE2krsrcfSjj0HpR/TrgdBRg55646Y7YpDEPtRQcnrRQAp9yc/5xS5Oerbs5/Gm8e9WrKBpXyq71Q5Ibp7/wAqAI7aLzpUTeVVjjOM49ePpW1p8WTcAuPsEMXmTupVXIzgKCQcEkqo4OM5xgGnrAV0u6vGXMbHyg3fPXH/AHyCfzPrUeqeXp/hzTLEeS9xdf6fOVALRg5SOMkMf4cvyAf3gq4q92+hE5Wsl1HQy+GIJ47lrfVbxNwJ093SJVHU5nGS44xgIh5zkY5ytRtlg1K8giZXihldNynAIUkZHJ6/U/jVTt6/0rqFtzq0MeqPtkht4IraVRuZ18tAq78KoGQvy47JySwLFt8y2JS5Jb7/ANI5hkZAN6kZ596QduD789qnn3yXLgqN+ckEgAY7Z/8A1VDjAB4I6/X2rM1G/UGjjHQ5pcEdR+dGO207ulAAR7H0/GgeoHfjNAGR0wOhJoAz0H4mgA4+po5x1A4oznqeM9KXHOGAXsfagDotHjIhjQANkbm3EHt/9YV0mmW0Us64cRu5w2HGT06qev4Zrm9N89CH2o4Byc8g/iOn1ro7a4gnId4sSjhkkzyP5MPrQB6NBot69pEV1K2ZQOCeCMeox/hVDWbDWLe3Pm+RdxH7rRSAMv4ZrnYtXjCCO0/dsvVGbKj6Z/xFXrTxDcWtk8UkdtPGTuKbuefUNx+INAHJ6hc31vJm8W5A5wZomBXn1A/z7VzuqagZSQW3qejOcj6cCup1LxPHLMRaq8MY4Ko+Qv4MP5VRnnM6rKv2cNnG9o+T36g80AYME6CMqsihjnIzjH6UwXRj2q0iuCOTtIz+Pauma9tBDhkty3TKna35Ef59qyLiS0kLN5zA46YXH59qAMy5liaMmFCvOM4/z/nNT6QkdxqdjHNIJEaeMMjKDkFsEH+VVFhtmDHe24cgBMg/lx2/WpNMuxa6laysH8uOZJGGADtB5/l/+qplezsa0HFVYuW11+Zp+KPD50m73Kw+xSk7G28jp8pPr7+n41R06WOJsq04UY5Cg5/Sun8SeJob/RSltbF4ZnMTmTBZCACCAMjvwc9q4lWK7docZ5wF/r+FZYeU3D31qejnVHC0sS/qkrwevpfou6/4Y6S5QXkKeTDI7kZUsRz9ay30q8tFYhApPTLjPpWjoyRRlJpQu7sGGSfzI/Wtq8vrieMIsKeWOoJwPyUH+dbnknEvZzs2G3Ox6YPGasw6HcvjeVROuRya25rwxRnMSxejKpH5YyT+dYtzfXEgypkMfP3cjP5ZOPxoAoX1v9luWixkDkE9x+BqvxwDVq4LMuTtG09ByP8AP8/wqt29R6GgBG689f5UUHjjBBHXNFAGveapHe6ba6emnWdqYTkzxvOzOduCSGkZRuPJ2qOQMelWtKhV0TykWSQkqCWP8hnI6e/b64aKDH94BucAH+db+kQPvi2pLK7/AHcDqM9PXP5UAb2o6bHJfafY3j+Tpocy3LwMHZYhku2ADghQxxg9M9K4zWtSm1fVrq/ucCSd92MDCr0CjAHQYHA7V3fi/TzZaNLqcke9541tYWV2BQkAuxB5+4CmMYw+QeOfNvTPHH51bbUUu+v9fiZpJzcu2n6/5fcKoLEBeWPvXouj2jr4bOlQIrz3INwmYyzO6gt5aYBIcruGO54OMZrhbWQidSEYqvLBAGOB+g780ya9mkuGn8xgxDL16KwIIA7DBIpRdnqVOPMrIHuGc7IuFY4Axk/4flVrS4BdyRQys3ls3JA/DJ+lXYtGm1G9uZbSylS1LblYrhFVhuUexIIIGenHPWrmnWjafiS4jAZHAyxzkjqNv09fXFJqzsNO6uQeJHisbCDSU06yaOMs8OofvFnkBOTuAk8s4+7nb0QVzR47Djiui129e/JkuF3uBtJfJMag4A9unQVzrYBOOnb6Uhgc+3pxRx7n0zRx7lc8ds0dPTPrQAfj7VYtQEBd0yBx/wDr/Oq/vwO4Aq6qkACJwwHbPX6f570AaNs1uqBt4hY9AUOD+I//AF9Kv2tzAGKSLtJ43ISQ30I5/wA+1YtvLCcIz+W44zng/WtKzXy5ArRxSqe6OQT+H+f5UAacMBkYmKfBYEjc5B/M8fnWXqsN0GYNcJKRzg84/LNdBaS2kiMhuSp6HcSD+JHbn2rB1C3ZLki1uo2Q9CB6+4OKAMGcp1Oc5/ukc+vWmCZhncqc8H5QD+lT3sRWY+a5yTgHGR+p/rVTIBwOR0OOM0AKXJGRkD2PFL5jjqSR055BpuCRjOffd+FJ1zx27UASBnYYBBweuBTGXacE/wCcUnTnt2460EnpkdeQBxQBraLIJRPYsmftCfJ6GRclfxOSv/AqolTMuQrbyMjnP+ff/OVshL9pVoEBkQhgVJOCD14rpLvQry4vvOtrUxwygSgiPlcj5l59Dmp2l6nS/wB5RT6x/J/5O/3ooabakBZJncD/AHCV/wAK07yd4oRtvWz2RMDj6/l0rovD3h1/IMkxcMDk/ul3fXP51z3jG2tbSby498kjDO3I5OR2H1qjmOcuLw/ddndhzlzkn8eaggnYTKdqucdMnB6etRSEF/lXGegH86YPRfz6UAdZ4f1qxtb4f23BLdWDIySW1vMYt4I4yRgkZxxkZ4+h5eYxtPIbdGjh3Eosjh2VewJwASB3AH0FR5Hf8hR+GcCnzO1ieVKXMAUsONvHHJAopRtGd6tnPY4/pRSKNCwgillcbwwHOGGDjtg+v+e1bOmtNb3qxQOZUT5kG0nHfPXBxnt/9audty8MoZWIAOQc4/H06/yrd8M6qbXXbad5EjEbF4nkL7Y5AMozbVZmUNg4A54BwDTSu7MUm0m1qafxI1SZrqPTGkgb7EBG5ikLfPgbucngHjt0+pPEnaBlM5B+ort9W8OajqcBkstmqTJgk2TiaRl7kx580AEnllHJHqK4iWN4ZGjlRo5UYqyuuCCDggg9DmqqRaeqsRSlFqydyxp203UaSKWidgpHQsM9P1rrr6x8NWDv59vfSMcE7pCFB/75B/DNcVA/lyqwGTxwOe9bFwuo69eiGws7m4mCZ8uCEs5HGTheo6VCV9EW2krs7t9dWDw7bS6NElwpjKND5rukXIVFCg5Ryoc4IBOwkFhiuT1qfULiWOK5tPsjP85QjlR2ODz+fPSn2MeqeHtOvobphbpcFGMUVyguVmQN5e6IHeoBYkhgo4HfANUR3b3IkvZHe5cbjh9zJ9Rn5fx9Py0qK1tLGdJ3T1ug1IwQ2EcMRLAAZKnO45GSW/zj+fPbG54IU56d+9dBqMFralXusTucnHmc/Tg+mOnSsa6uRM3+rRV+6AoACgegH8881malbGMZGM9+2KO3Tg8ZxW/q/im51XQbLSZrLS4Lazx5T29oscvAI5ccnPU5PJwTk1gDBI/XigCxYBTex+ZkANk4XoR0/XFXblMykz+XGxJwegP4/wBPeqdoMo23y2Y9VfqR7fnUzSJt2Eyq3YFif/1d6AJWM6na4RlP94feH68U4Sq37vy1LdsjP0759apKFG4GQ7fQ8980iGJMFZOf900AbUMaGRS8zo46AjcfwPWtCZzgIXiHHuhJ+h4NYkDSOF8mUuB2HI/I9P51tfYp5rcNNCzADOUJAB9wOPXvQBm6pbwuA3kzq3Vj5QAP5H+nrWIFKuBke28dB+Nb9zDGgMbb4SegzkH9eKwrlMMTu3f7Q6HigBh2dQRnHGRTRjI3BmX64+tSZQ8YYHthhj0qPA6/w/lQBKnk453A9M5oEfJARyPbjP401EDDhhuHTAJo8raCWRiAfpkUAaNtqMlmgFshXH909/qD/nNbdh4hvTZTkufNtiJPlO7KHg+vQ7T9Ca5EhSc7sAcHd1q7pN19mvYiwLRk7JFA6oRhufp/nipktNDfDySnyy2ej+fX5PX5HVw+I7m5gAkuSq46M7kgdexH+frWHrV1HK5VCrMepCAdfpyfrVa5huLOaWFmJ2MVDZ4bB4I+uRiqbSSxEng55O4f5/z+dUnfUylFwk4y3RC4Ifnhs9wfz5ppBHDKQffinSSNIecZ69vSmA456D2PegkOexyOmfSpY7ho7aaFVjKSlS26NWcEZxtYjKjnkAjPGc4qLHOMc9MUHkjGOlAAGK8DBHuoNFOTfg7HwM/3sUUAOjlMeR1B7Z6+1Wo3gmYGTdCcgkqePX+n/wBY1Qz07il4B6dOvPWgD0Dw5b219brZLcw+dI2V8w4UDHU/Lz19/wCtddJ4Q8ezeU+nX+rSWuNvl2Gr+dIuM8+UJCwHHsOleLW1zNayCS1mlhkH8UbFT+YrePjbxCJFf+0AsigJkQRg4Hr8vPuTye9VGUo7OxMoRn8SueuHwTrtram4x4mtr7dh2h8P21i5PU5uFl3nsTnrnmvOdVg8S6lPJp9/qd/LbxuQ63d2cIyn+JWY5Ix2zzVWX4l+M5LfyG8RX3lhdoCuAQM5xkDPUk1z0+rX85JmvJnJO4nfj8qbqTe7ZKo007qK+46PT9KsrHma7VZipKtLhUyCOh9ee/5VF4ourG0McWk3ULiZPMdbPcsSZz8mWYsSMd/zrlGcu2523N3LEnPtSAZwMZz0x1zU3LtrcfJKzjnIH1pnPXtjse1HPBDc/wAqBj2/GkMDnnOc8dfSg8knrznJ6mjjjv60dsH8OaAFGQRjqPSnNLIwO/5uM8jpTMfl60mO3fr1oAlG0j5ZMEnGGHHtTtrKCGwUIz0znHTmocnIGcdvpSqxVgy8MOcg4oAv6edr52KRnoP8g11+lPHMMR3eJFHKk4PvkGuFFzKMfNnHTIBrUsNbFumJLZZG5G7dt47Z4PFAHRavbRkhbh8dh8mc/iBiuc1EW4QeWu7PVyP8cfnWk3ieKXZ5sDhcAtsbkfrz+NVp9S0mU5NncE4zu4U+meKAMFlIJ2sGz79fwpnU56Z79qv332KQb7aVgzdQ+4n8aoEDdhee31oAUN78+/8AL+VDEndnJbvntW34G0u31zxv4e0m93i0v9Rt7WXy2AcJJKqnBx1wfSva/FPwf0HSvFPhfTrW2uYLnU9XubJLS9vRcRXNtESBP5kSqYyTjKZLDODjBoA+eVwSSBnHanK7kAK5AA69MCvT9I+EzanYWEs2t21nfalFd3VnZeS8mYLfduZnHCklTgc+/pWtr3ws0ifRtPu9G1mGxvYfDFprl3YyxyuXVgvnTCT7o5YYQZ/CgDyi/njngtXZi1ysZjkAJOQvCnP04/4DVJXJOUUZ7d/5/hXbfGPwjpPgvxrLo2h6jPfRJFE7LMn7yJniR8FtoDZ3ZGBwCAec12MfwTigufD8moa0RY3ur22mXcf2UwXEJlBK4U7iCcbQXVcEglcZpJWVi6k3UlzPc8Vbrj+uaQ55yORxjFem6/8ADXTbC08QapB4ntU0nTdUk0qLz7aYyTSiNnEfyJ975SuSAvBOcYFP8c/DR9NvfEU1tJaWttpc+n25gjMjgtcwq4IZueuSc9zxxTIPMOB/Dn0zQz5GBgDuAMZr2Ox+Bs02p3Vld+JLG1mXWJNEgBt5X864WFZRjH3VIbGT0x3rivHfgseFtP0K/ttWt9UstVjmaKaGJ4trxSGORcOAcBhwcDPoKAOQ4/iBz+VFKNoHzKxz0OcUUAID6dPQ0c/wk45xUsNvJcSFIlDSYLbeh47Adz7CpUsLmSOORYsrLnYARubBwdq5yaTaW5LnGO7Kv0zj0oHtz9asyWF3HKkctrOsjkKq+WcntgDuaVNPupQTDCZiBk+SRJtHqQucfU0cy7i9pDe5U9uPrSjkgcHnpjrV6PSdQlQNHZXBVhuAWMkkeoHUjkcj1Fa+n+HYp/C2rahcTql1by262yLcx7HVy3mE89sJ3GN3NLmj3F7WH8y+85rsM52/1oOD9eOavjSL/wC2PbC2kFwgDFOO+Mc596S10y5nneLCpsjaRmdtq7V68/Xj69elHNHuHtYWvzIonPTHv0pe4x64GT0q22l3ilQ1u+WUOAuGLLjO4AdR7jip49DvTcpBKkdu7YCmVwAxPQDrknpx+OKOePcTrU1rzIzB1AXnp270AE8DnPtWiNF1EySRi1fcmN4yMDPTJzj1qI6ZeCXyTCwn7wkgSZ/3M56c9KOePcarU3tJfeU+M8fh7UD3PH0q1JYXMaSM8W0R4MilhvTtyvUcn0pzaZdiVoTGpmQHMayKXGOT8uc9AafMu4/aw7op849QO3pRxj/69WmsJlCFxGgdQ43yopKnocE+lTNo+oKI2a1fEnCkkYPXn6YBOenFLmXcTqwW8l95n5J5zzR+AFWrixube3SeWMeQ/CsrBgTz6H2P5GnNp15GA08DwqcDMv7oN9C2AafMu4/aQ7op98kD1+tAA56nHpV9dJvTGHEIaMjeXDrt2jqd2cY9/pTF0y7eYwiH94u0dRg7uRg98+1LmXcXtYfzL7ymT1ySc9frQT1Oc565FXm0q9WVYpINjlDJ87AfKDjOc9jxUN3aXFmUF1EV3jcpJyGA44IpqSezGqkG7JofpGoXWkapZ6jp0phvbOZLiGUKG2yKwZDggg4IBwcj2rqYfij4vidHXV9zR6jJq0Ze2hcx3Tkl5Fyh2glmJUYXk8VxXH+NL9MA9OvWmWeq+FfjBdeHvCJ0oadJeXqx3UUNzPPGYofPzvKp5W8feztEgUnkiuPPjjxGRJnUM79IXQ2/cR/8eQ24i+7/ALI+b73vXNDvjr6YzxQcfX8etAG34l8Vaz4lura51m9Fxc28awxzCFI5CqgBdzIoLkADliTx1ra1X4o+MdUiiS91fPlXUV8HjtIY3NxGP3chdUDMw9STnvnFcV2wOT/SjocjtzzQB0niHxx4g8Q2V1aateRy21zeDUJkjtYoQ9wIygf5EGDtJzjgkknJ5rQg+KPjG31PVL+PWSLnU1hS7P2eErJ5ShYztKFQVCjBUA+9cXwPc0d8A+2RQB2R+Jvi/wC3LeHVszrqR1YP9mi/4+jGIzJjZj7gA2/d74zzWFqniDVNW0vTdP1C586z07zfsqeWi+V5rmR+QATliTyTjtgcVlcHrgdqOvJBOe/qaAEooNFAF3R5vs2rWUxbaI5kJIPGA3PP0rS8Tn7FqVpb28mPscahWT+FixfI9/mFYGafJI8sm+Ri7HGSxJziocby5jGVHmqKfl/X6ly31W+htpbdLlxDLkupAbOeCee+KpwyNFKkiEh0bcpHYjpTV5yPxpMnnk89feqskaKEVey3LN5e3V84a6nlmIJ272zjJ7DtXRaLbRzfDzxPcyqWlt7iyWIknCBzLuwOmTsHPXr6nPKqAVY/3Rn9au22oXVvp97psM22zu2R5o9oO8x7ihzjIxubp60JJaAoxSsloMa/uWshalx5IIyAihjjONzAZI5PBNa0QWLwm90h/eFmtDzxgsG/oa57t0p/myeV5W9vLzu2Z4z649feplC+xnUoqVlHTW4+1uJrS4Sa2cxTIflYHkdqkmvrmZIRLO7+USyZPKknJOe5qrnjjjjn3ozzwBVWW5o4Rb5mtS7Nqd7NbtDLdzPCWJ2s3Uk5Ofxqn+I5HpSZJ60bjnOec5z3oSS2CMVHSKsWbK8nsZfNtXCvtIJKhgQRggg8Hr6VNpk7HXLSeaQsTcozOx5PzDJNUMnA5oz9PTpQ4pilBSv3ehpa+4bV7lQQUjbyQQOgXj+lVkvLlFdFuJlV1CSAMcEDgA/QAVAo3Nz6E/pmm5oUUlYI01GKi+hdsNTu9PVxZztFvIJwB29z0qK4uri54nnklG4t8zk8k5JA96g3H6denFJmiyvcPZxUua2o+SR3RFeR2VBhQxyAO+PSrTaldmKGPz/9QQUYKAwwTj5sZP3j16Zqow2twT0H6ihRuViewzx9QKLJjcIvdHQqzT+E5p2fMkcjQZz1DOj/AM91YDyySRxo7syRjCKTwoPPApvmv5ZjDkRkglQeCR0OPWm5pRjy3IpUuS/m7i/kccf/AF6Dx6Ht9aXGYySTwQB+tNzjpxxVGopz6c9c0cZzgn2PpSdulBOewAoAXsOmKO/I78gUmeckCigBR2wR64xR1xk8fypQNwcknIGf1/8Ar03PoB0oAXOP6j2pBj8T+lGeMUZPPv1xQAuCckLx7UUhOTmigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Close up view of tricuspid valve from a four chamber view of a 2-D echocardiogram shows vegetations on the ventricular surface of the tricuspid valve due to endocarditis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_466=[""].join("\n");
var outline_f0_29_466=null;
var title_f0_29_467="Blocked sinus passage 2 PI";
var content_f0_29_467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Chronic sinusitis with polyps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 481px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts a person who has chronic rhinosinusitis with polyps (abnormal growths inside the nose or sinuses). Scientists do not know why polyps develop.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_467=[""].join("\n");
var outline_f0_29_467=null;
var title_f0_29_468="Toe curls PI";
var content_f0_29_468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Toe curls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Curl your toes around the edge of a book. Then straighten them. Do this over and over again for 2 minutes, twice a day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_468=[""].join("\n");
var outline_f0_29_468=null;
var title_f0_29_469="Intravenous magnesium sulfate in acute myocardial infarction";
var content_f0_29_469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intravenous magnesium sulfate in acute myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/469/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/469/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/469/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/469/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/469/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/469/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/29/469/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of ancillary modalities that may be beneficial in the management of the patient with acute myocardial infarction (MI). These have included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , angiotensin converting enzyme (ACE) inhibitors, beta blockers, and perhaps nitrates and intravenous magnesium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential benefit of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    in patients with acute MI has been controversial. Available evidence for and against the use of this agent will be reviewed here. The role of magnesium and hypomagnesemia in other cardiovascular diseases is considered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16085?source=see_link\">",
"     \"Significance of hypomagnesemia in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STUDIES DEMONSTRATING BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pooled analyses of early trials in which more than 1300 patients presenting with acute MI were randomized to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    or placebo revealed a significant decrease in mortality in those treated with magnesium [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A myocardial protective effect of magnesium was also demonstrated in animal models of ischemic arrest and reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent studies, including the Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) and a smaller study of patients not treated with fibrinolytics (see below), demonstrated a benefit of magnesium therapy comparable in magnitude to that obtained with thrombolysis. These observations suggested an important role for magnesium in the management of acute myocardial infarction.",
"   </p>",
"   <p>",
"    The mechanisms by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    might protect the myocardium in the setting of ischemia and infarction are not known. The following may be important:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enhanced collateral flow",
"     </li>",
"     <li>",
"      Decreased free radical formation",
"     </li>",
"     <li>",
"      Reduced afterload",
"     </li>",
"     <li>",
"      A direct antiarrhythmic effect",
"     </li>",
"     <li>",
"      Limited reperfusion injury due to reduced calcium influx following relief of ischemia",
"     </li>",
"     <li>",
"      Coronary artery dilatation",
"     </li>",
"     <li>",
"      Inhibition of platelet function",
"     </li>",
"     <li>",
"      Attenuation of catecholamine release",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to further elucidate the potential antiarrhythmic effect, one clinical study evaluated the role of magnesium on the action potential duration during ischemia. When compared to placebo, magnesium prevented the increase in action potential duration and the prolongation in membrane repolarization, which normally occurs in the ischemic myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/5\">",
"     5",
"    </a>",
"    ]. This is associated with a reduction in QT dispersion, which reflects an enhancement in the homogeneity of repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     LIMIT-2 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;LIMIT-2 was a double-blind randomized trial in which 2316 patients with suspected acute MI received either intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    or placebo along with other currently accepted therapies for MI, including thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/7\">",
"     7",
"    </a>",
"    ]. Thirty-five percent of the patients received a fibrinolytic agent, usually streptokinase, and 66 percent received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . The presence of an acute MI was confirmed in 65 percent of cases.",
"   </p>",
"   <p>",
"    An important design feature of this trial was that magnesium was administered",
"    <strong>",
"     prior",
"    </strong>",
"    to a fibrinolytic agent. A treatment effect was observed in all subgroups, including those receiving thrombolysis. Important benefits in the patients treated with magnesium (compared to placebo) included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 24 percent reduction in 28-day mortality (7.8 versus 10.3 percent).",
"     </li>",
"     <li>",
"      A 25 percent reduction in the incidence of left ventricular failure.",
"     </li>",
"     <li>",
"      A 21 percent reduction in mortality from ischemic heart disease with long-term follow-up (18 versus 22 percent)&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patients not treated with fibrinolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small but strikingly positive trial, 194 patients with an acute MI not considered candidates for fibrinolytic therapy were randomized to receive either intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/9\">",
"     9",
"    </a>",
"    ]. Benefits of magnesium compared to placebo included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in in-hospital mortality (four versus 17 percent). A mortality benefit was also seen in elderly patients over age 70 (nine versus 23 percent).",
"     </li>",
"     <li>",
"      A lower incidence of both arrhythmias and left ventricular dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STUDIES SHOWING NO BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite these findings, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    remains controversial due to later trials that have not demonstrated efficacy in acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The most important are ISIS-4 and MAGIC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ISIS-4 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Fourth International Study of Infarct Survival (ISIS-4) enrolled 58,050 patients with suspected MI to assess the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , mononitrate, and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <strong>",
"     No",
"    </strong>",
"    beneficial effect of magnesium could be demonstrated, even after the analysis of multiple subgroups. These investigators concluded that there was no role for magnesium sulfate in patients with acute MI.",
"   </p>",
"   <p>",
"    The conclusions of the ISIS-4 trial have been challenged based upon the following possible flaws in the study [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnesium infusion was typically administered",
"      <strong>",
"       after",
"      </strong>",
"      initiation of fibrinolytic therapy. As an example, magnesium was given within two hours after the start of the fibrinolytic infusion in about one-half of all patients, not before as in LIMIT-2.",
"     </li>",
"     <li>",
"      The median time to randomization from onset of chest pain was eight hours versus only three hours in LIMIT-2.",
"     </li>",
"     <li>",
"      Failure to have produced adequately elevated magnesium levels at the time of coronary artery reperfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This last problem may have prevented magnesium from limiting reperfusion injury, since reperfusion was likely to have occurred prior to the administration of magnesium. This hypothesis is supported by two animal studies showing the importance of magnesium administration before reperfusion is achieved&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=see_link\">",
"     \"Ischemic reperfusion injury of the heart\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     MAGIC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MAGIC trial addressed the major limitations of ISIS-4 by randomly assigning 6213 patients with an ST elevation MI to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    (2 g IV over 15 minutes followed by 17 g by infusion over 24 hours) or placebo",
"    <strong>",
"     prior",
"    </strong>",
"    to reperfusion; the patients were stratified by whether or not they were eligible for reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/11\">",
"     11",
"    </a>",
"    ]. Only 25 percent of patients underwent reperfusion, mostly with fibrinolytic therapy.",
"   </p>",
"   <p>",
"    At 30 days, there was no overall mortality benefit (15.3 versus 15.2 percent). In addition, there was no benefit or harm in eight prespecified subgroups (including time to therapy, whether or not reperfusion was performed, and age) or in 15 other exploratory subgroups. Thus, these results confirm those of ISIS-4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patients undergoing primary angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of magnesium therapy delivered before, during, and after primary (direct) angioplasty was evaluated in another study of 150 patients; compared to placebo, magnesium did not affect the incidence of ventricular arrhythmias within the first 24 hours or wall motion score, left ventricular ejection fraction, or incidence of death or heart failure at 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     USE IN UNSTABLE ANGINA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnesium may have a therapeutic role in unstable angina, but data are limited. One study randomized 62 patients with unstable angina to a 24 hour infusion of magnesium or placebo and found that magnesium reduced the frequency of ischemic ECG changes, improved T wave changes, and reduced creatine kinase-MB release and urinary catecholamine excretion in the acute phase of unstable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon ISIS-4 and MAGIC, there appears to be",
"    <strong>",
"     no value",
"    </strong>",
"    from routine administration of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    in the setting of acute myocardial infarction (MI). The 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on ST elevation MI recommended that routine intravenous magnesium should",
"    <strong>",
"     not",
"    </strong>",
"    be given but that magnesium therapy is reasonable in two settings [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For documented magnesium deficiency, particularly in patients who were treated with diuretics prior to the acute episode.",
"     </li>",
"     <li>",
"      For torsades de pointes associated with a prolonged QT interval. In this setting, magnesium should be given as an intravenous bolus of 1 to 2 grams over five minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No changes to this approach were made in the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The data do",
"      <strong>",
"       not",
"      </strong>",
"      justify the routine use of magnesium. Although it had been suggested that benefit might be most likely in patients who are not candidates for reperfusion, this subgroup did not benefit in MAGIC [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Magnesium supplementation should be given for hypomagnesemia or torsades de pointes, as recommended by the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/469/abstract/18\">",
"       18",
"      </a>",
"      ]. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=see_link\">",
"       \"Evaluation and treatment of hypomagnesemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      has a potentially deleterious effect on atrioventricular conduction; as a result, relative contraindications include greater than first-degree AV block and sinus bradycardia.",
"     </li>",
"     <li>",
"      Patients with impaired renal function may require a lower dose since magnesium is excreted solely by the kidneys.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/1\">",
"      Teo KK, Yusuf S, Collins R, et al. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991; 303:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/2\">",
"      Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/3\">",
"      Horner SM. Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality. Meta-analysis of magnesium in acute myocardial infarction. Circulation 1992; 86:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/4\">",
"      Hearse DJ, Stewart DA, Braimbridge MV. Myocardial protection during ischemic cardiac arrest. The importance of magnesium in cardioplegic infusates. J Thorac Cardiovasc Surg 1978; 75:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/5\">",
"      Redwood SR, Taggart PI, Sutton PM, et al. Effect of magnesium on the monophasic action potential during early ischemia in the in vivo human heart. J Am Coll Cardiol 1996; 28:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/6\">",
"      Parikka H, Toivonen L, Naukkarinen V, et al. Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute myocardial infarction. Eur Heart J 1999; 20:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/7\">",
"      Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/8\">",
"      Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/9\">",
"      Shechter M, Hod H, Chouraqui P, et al. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 1995; 75:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/10\">",
"      ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/11\">",
"      Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/12\">",
"      Santoro GM, Antoniucci D, Bolognese L, et al. A randomized study of intravenous magnesium in acute myocardial infarction treated with direct coronary angioplasty. Am Heart J 2000; 140:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/13\">",
"      Antman EM. Randomized trials of magnesium in acute myocardial infarction: big numbers do not tell the whole story. Am J Cardiol 1995; 75:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/14\">",
"      Th&ouml;gersen AM, Johnson O, Wester PO. Effects of intravenous magnesium sulphate in suspected acute myocardial infarction on acute arrhythmias and long-term outcome. Int J Cardiol 1995; 49:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/15\">",
"      Christensen CW, Rieder MA, Silverstein EL, Gencheff NE. Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model. Circulation 1995; 92:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/16\">",
"      Herzog WR, Schlossberg ML, MacMurdy KS, et al. Timing of magnesium therapy affects experimental infarct size. Circulation 1995; 92:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/469/abstract/17\">",
"      Redwood SR, Bashir Y, Huang J, et al. Effect of magnesium sulphate in patients with unstable angina. A double blind, randomized, placebo-controlled study. Eur Heart J 1997; 18:1269.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 59 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_469=[""].join("\n");
var outline_f0_29_469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STUDIES DEMONSTRATING BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIMIT-2 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patients not treated with fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STUDIES SHOWING NO BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ISIS-4 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MAGIC trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patients undergoing primary angioplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      USE IN UNSTABLE ANGINA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=related_link\">",
"      Ischemic reperfusion injury of the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16085?source=related_link\">",
"      Significance of hypomagnesemia in cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_29_470="Regulation of magnesium balance";
var content_f0_29_470=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Regulation of magnesium balance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/470/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/470/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/470/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/470/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/470/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/470/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/29/470/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 26, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnesium balance, like that of other ions, is a function of intake and excretion. The average daily magnesium intake is 360 mg (15 mmol). Approximately one-third of this magnesium is absorbed, principally in the small bowel through both a saturable transport system (presumably mediated by a channel encoded by the TRPM6 gene) and passive diffusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two other processes occur in the gut: the secretion of approximately 40 mg (1.7 mmol) in intestinal secretions; and the absorption of another 20 mg (0.8 mmol) in the large bowel. In the healthy adult, there is no net gain or loss of magnesium from bone so that balance is achieved by the urinary excretion of the approximately 100 mg (4.1 mmol) that is absorbed. Changes in intake are balanced by changes in urinary magnesium reabsorption, principally in the loop of Henle and the distal tubule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UNITS OF MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discussing the factors responsible for the regulation of magnesium balance, it is useful to review the different units that may be used to measure the plasma (or serum) magnesium concentration. Laboratories in the United States usually report the results in units of",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    while other countries primarily use",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    The relationship among these units can be expressed by the following equations:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    &nbsp;= &nbsp;",
"    <span class=\"nowrap\">",
"     [mg/dL",
"    </span>",
"    &nbsp;x &nbsp;10] &nbsp;&divide; &nbsp;mol wt",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    &nbsp;= &nbsp;",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    &nbsp;x &nbsp;valence",
"   </p>",
"   <p>",
"    Since the molecular weight of magnesium is 24.3 and the valence is +2, 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    is equivalent to 0.50",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and to 1.2",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Thus, the normal range of plasma magnesium concentration of 1.4 to 1.7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    is equivalent to 0.70 to 0.85",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and 1.7 to 2.1",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RENAL HANDLING OF MAGNESIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnesium transport differs from that of most other ions in that the proximal tubule is not the major site of reabsorption. About 80 percent of the total plasma magnesium is filtered at the glomerulus. Only 15 to 25 percent of the ultrafiltrable magnesium is reabsorbed passively in the proximal tubule (down concentration gradients generated by the reabsorption of sodium and water) and 5 to 10 percent in the distal tubule. Micropuncture studies (in which small pipettes are inserted into different nephron segments) indicate that the major site of magnesium transport is the thick ascending limb of the loop of Henle where 60 to 70 percent of the ultrafiltrable magnesium is reabsorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Loop of Henle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cellular mechanisms of magnesium transport in the thick ascending limb are incompletely understood. The bulk of magnesium transport appears to be passive, occurring by paracellular diffusion between the cells and being driven by the favorable electrical gradient resulting from the reabsorption of sodium chloride (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ]. Paracellular magnesium reabsorption appears to be facilitated by a tight junction protein called Claudin-16 that is encoded by the paracellin-1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors controlling magnesium transport act through changes on the voltage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    permeability of the paracellular pathway. Thus, decreased reabsorption and magnesium wasting can be induced by the administration of a loop diuretic, which inhibits sodium and chloride reabsorption, or by mutations in paracellin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=see_link\">",
"     \"Diuretics and magnesium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other factors alter magnesium transport.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma magnesium and calcium concentration &mdash; Loop magnesium reabsorption (particularly in the cortical aspect of the thick ascending limb) varies with changes in the plasma magnesium concentration, which is the main physiologic regulator of urinary magnesium excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Hypermagnesemia inhibits loop magnesium (and calcium) transport, while hypomagnesemia stimulates magnesium transport in both normal and magnesium depleted animals, thereby decreasing further magnesium losses.",
"      <br/>",
"      <br/>",
"      Hypercalcemia also inhibits magnesium (and calcium) reabsorption, leading to hypermagnesuria and hypercalciuria. In vivo microperfusion studies have demonstrated that [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased",
"      <strong>",
"       intraluminal",
"      </strong>",
"      calcium or magnesium enhances calcium or magnesium absorption.",
"     </li>",
"     <li>",
"      Elevation of the plasma (ie,",
"      <strong>",
"       peritubular",
"      </strong>",
"      ) concentration of magnesium or calcium inhibits both magnesium and calcium reabsorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings cannot be explained by changes in passive forces, but by the activity of a calcium (and magnesium) sensing receptor located on the peritubular side of thick ascending limb cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Binding of calcium or magnesium to the extracellular domain of the receptor initiates a series of intracellular signals, including the modulation of adenylate cyclase activity and activation of phospholipase C, which result in the inhibition of apical (luminal) potassium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Secretion of potassium into the lumen via these channels has two functions: it provides potassium for sodium chloride reabsorption by the Na-K-2Cl cotransporter; and it makes the lumen electropositive, which permits passive calcium and magnesium reabsorption. Thus, inhibition of the apical potassium channels in the cortical thick ascending limb will reduce both active sodium transport and passive calcium and magnesium reabsorption. Claudin-16, which likely serves as a cation-selective pathway, allows positive charged species to diffuse into the lumen, thereby augmenting calcium and magnesium reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/14\">",
"     14",
"    </a>",
"    ]. Further discussion of the role of this receptor in the modulation of calcium and sodium transport is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hormones &mdash; No single hormone has been implicated in the control of renal magnesium reabsorption. A number of hormones have been shown to alter magnesium transport in the thick ascending limb in experimental studies. These include PTH, calcitonin, glucagon, AVP and the beta-adrenergic agonists, all of which are coupled to adenylate cyclase in the thick ascending limb. Postulated mechanisms include an increase in luminal positive voltage (via activation of basolateral membrane chloride conductance and apical Na-K-2Cl cotransport) and an increase in paracellular permeability (possibly by phosphorylation of paracellular pathway proteins) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/15\">",
"       15",
"      </a>",
"      ]. It is not known if these effects have any important role in normal magnesium hemostasis.",
"     </li>",
"     <li>",
"      Other factors &mdash; Metabolic alkalosis stimulates and metabolic acidosis, hypokalemia and phosphate depletion inhibit magnesium reabsorption in the loop of Henle contributing to changes in urinary magnesium excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/1\">",
"       1",
"      </a>",
"      ]. The mechanism for these changes is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Distal reabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about the mechanisms and regulation of the distal reabsorption of magnesium, which appears to occur primarily in the cortical collecting tubule. Studies in immortalized distal tubule cell lines suggest that entry of filtered magnesium occurs through magnesium channels in the apical (luminal) membrane. This is driven by a favorable transmembrane voltage consisting of an electronegative cell interior; in addition, the free magnesium concentration within the cell is less than 1.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evidence suggests that magnesium exits through the basolateral membrane via a sodium-magnesium exchanger, such as the protein product of the cyclin M2 (CNNM2) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/17\">",
"     17",
"    </a>",
"    ]. Mutations in the CNNM2 gene have been identified in patients with autosomal dominant hypomagnesemia. The driving force for this exchanger is the low sodium concentration inside the cell (10 to 15",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    compared with that in the extracellular fluid, thereby favoring sodium entry and subsequent magnesium exit.",
"   </p>",
"   <p>",
"    Distally acting diuretics can affect magnesium handling.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     Amiloride",
"    </a>",
"    , a magnesium sparing diuretic, stimulates magnesium reabsorption via hyperpolarization of the membrane voltage, thereby increasing the driving force for magnesium entry [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/16\">",
"     16",
"    </a>",
"    ]. Studies of the effects of the thiazide-type diuretics have been conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies with isolated distal tubule cells indicate that magnesium transport is stimulated through changes in membrane voltage similar to those observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=see_link\">",
"       \"Diuretics and magnesium balance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      However, the clinical use of thiazide diuretics is occasionally associated with hypomagnesemia and renal magnesium wasting; in addition, Gitelman syndrome, which is due to an abnormality in the gene coding for the thiazide-sensitive cotransporter, is characterized by hypomagnesemia due to urinary magnesium wasting [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"       \"Bartter and Gitelman syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"       \"Causes of hypomagnesemia\"",
"      </a>",
"      .) It is possible that the potassium depletion associated with these conditions is responsible for the hypomagnesemia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/1,18\">",
"       1,18",
"      </a>",
"      ]. Alternatively, hypomagnesemia may result from accelerated magnesium reabsorption at",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      -sensitive sites located in the cortical collecting tubule. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=see_link\">",
"       \"Diuretics and magnesium balance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mutations of genes that encode proteins not previously appreciated to be involved in transepithelial magnesium transport are associated with clinical renal magnesium loss. These include the genes for Na,K-ATPase and the epithelial magnesium channel TRPM6. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Activation of TRPM6, which increases distal magnesium reabsorption, is dependent upon stimulation of the renal epithelial growth factor receptor. This was shown via the discovery that mutations in the epithelial growth factor (EGF) gene cause isolated autosomal recessive renal hypomagnesemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/20\">",
"     20",
"    </a>",
"    ]. The defect specifically causes impaired basolateral sorting of pro-EGF. The relationship between EGF and magnesium handling may explain the finding of hypomagnesemia in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that may modulate distal tubular magnesium reabsorption include phosphate depletion and metabolic acidosis, which may inhibit reabsorption similar to effects in the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, there is some evidence that magnesium depletion, in the absence of renal disease, results in enhanced magnesium reabsorption due to intrinsic adaptation. Studies in isolated distal tubular cells indicate that exposure to magnesium-free culture media results in a rapid increase in entry rate and a later recruitment of new or formed transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast to changes in loop transport associated with changes in plasma magnesium, this adaptation would allow selective enhancement of magnesium transport, independent of sodium and calcium, in response to magnesium depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REGULATION OF PLASMA MAGNESIUM CONCENTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to other ions, magnesium is treated by the body as an orphan: there are no hormones that modulate urinary magnesium excretion and bone, the principal reservoir of magnesium, does not readily exchange with circulating magnesium. This is in marked contrast to the roles of aldosterone and atrial natriuretic peptide in sodium excretion, antidiuretic hormone in water excretion; aldosterone and cell potassium stores in the regulation of potassium balance; and PTH, vitamin D, calcitonin, and bone stores in the maintenance of calcium balance.",
"   </p>",
"   <p>",
"    The inability to readily mobilize magnesium stores means that, with negative magnesium balance, the initial losses come primarily from the extracellular fluid; equilibration with bone stores does not begin for several weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, the plasma magnesium concentration falls rapidly with negative magnesium balance, leading to a marked reduction in magnesium excretion unless urinary magnesium wasting is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .) It is the enhanced reabsorption in the loop of Henle and distal tubule and fall in urinary magnesium excretion that protects the plasma magnesium concentration against further losses. The fractional excretion of magnesium, which is between three and five percent in subjects with normal renal function ingesting a typical diet, can fall to below 0.5 percent with magnesium depletion due to extrarenal losses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=see_link\">",
"     \"Evaluation and treatment of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversely, there is no protection against hypermagnesemia with loss of renal function. In this setting, continued intake leads to magnesium retention that is predominantly in the extracellular fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=see_link\">",
"     \"Causes and treatment of hypermagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CELLULAR MAGNESIUM STORES AND CYTOSOLIC MAGNESIUM ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total intracellular magnesium content approximates 8 to 10",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (10 to 20",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    However, most of the cell magnesium is bound to ATP and other intracellular nucleotides and enzyme complexes. Some studies, using magnesium-sensitive dyes based upon the FURA compound, indicate that the free cytosolic concentration is in the range of 0.6 to 0.8",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (1.2 to 1.6",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/470/abstract/22\">",
"     22",
"    </a>",
"    ]. Changes in the plasma magnesium levels alter cellular magnesium content slowly. It is not yet known how magnesium enters cells, but energy is not required because of the favorable electrochemical gradient. As the intracellular free magnesium is significantly below electrochemical equilibrium, however, there must be some type of energy-dependent extrusion mechanism. An ATP-dependent sodium-magnesium exchanger has been described in several tissues but its physiologic importance is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnesium balance is a function of intake and excretion. The average daily magnesium intake is 360 mg (15 mmol). Changes in intake are balanced by changes in renal magnesium reabsorption. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eighty percent of the total plasma magnesium is filtered at the glomerulus. Fifteen to 25 percent is reabsorbed in the proximal tubule; 60 to 70 percent is reabsorbed in the thick ascending limb of the loop of Henle; and 5 to 10 percent in the distal tubule. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Renal handling of magnesium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of magnesium transport in the thick ascending limb occurs by paracellular diffusion between the cells and is driven by the favorable electrical gradient resulting from the reabsorption of sodium chloride. Diffusion is facilitated by a tight junction protein called Claudin-16. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Loop of Henle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The plasma magnesium concentration is the major physiologic regulator of urinary magnesium excretion. Hypermagnesemia inhibits loop magnesium transport (thus increasing urinary excretion of magnesium), while hypomagnesemia stimulates magnesium transport (inhibiting its excretion). Other factors that decrease magnesium transport in the loop of Henle include hypercalcemia, metabolic acidosis, hypokalemia, phosphate depletion, the administration of loop diuretics, and mutations in paracellin-1 and related proteins. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Loop of Henle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that alter distal tubule magnesium transport include diuretics, genetic mutations, phosphate depletion and metabolic acidosis. Whereas",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      , a magnesium sparing diuretic, stimulates magnesium transport, thiazide diuretics are occasionally associated with magnesium wasting and hypomagnesemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Distal reabsorption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone magnesium is the principal reservoir of magnesium. Because bone magnesium does not readily exchange with circulating magnesium, the plasma magnesium concentration falls rapidly with negative magnesium balance. This leads to a marked reduction in magnesium excretion providing urinary magnesium wasting is not present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Regulation of plasma magnesium concentration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no protection against hypermagnesemia with loss of renal function. In this setting, continued intake leads to magnesium retention that is predominantly in the extracellular fluid. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Regulation of plasma magnesium concentration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/1\">",
"      Quamme GA. Renal magnesium handling: new insights in understanding old problems. Kidney Int 1997; 52:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/2\">",
"      al-Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 1994; 24:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/3\">",
"      Shareghi GR, Agus ZS. Magnesium transport in the cortical thick ascending limb of Henle's loop of the rabbit. J Clin Invest 1982; 69:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/4\">",
"      Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med 2005; 20:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/5\">",
"      Quamme GA, de Rouffignac C. Epithelial magnesium transport and regulation by the kidney. Front Biosci 2000; 5:D694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/6\">",
"      Simon DB, Lu Y, Choate KA, et al. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 1999; 285:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/7\">",
"      Kausalya PJ, Amasheh S, G&uuml;nzel D, et al. Disease-associated mutations affect intracellular traffic and paracellular Mg2+ transport function of Claudin-16. J Clin Invest 2006; 116:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/8\">",
"      Quamme GA, Dirks JH. Intraluminal and contraluminal magnesium on magnesium and calcium transfer in the rat nephron. Am J Physiol 1980; 238:F187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/9\">",
"      Quamme GA. Effect of hypercalcemia on renal tubular handling of calcium and magnesium. Can J Physiol Pharmacol 1982; 60:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/10\">",
"      Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/11\">",
"      Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone 1997; 20:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/12\">",
"      Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996; 50:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/13\">",
"      Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 1996; 271:C103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/14\">",
"      Hou J, Shan Q, Wang T, et al. Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. J Biol Chem 2007; 282:17114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/15\">",
"      de Rouffignac C, Quamme G. Renal magnesium handling and its hormonal control. Physiol Rev 1994; 74:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/16\">",
"      Dai LJ, Friedman PA, Quamme GA. Acid-base changes alter Mg2+ uptake in mouse distal convoluted tubule cells. Am J Physiol 1997; 272:F759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/17\">",
"      Stuiver M, Lainez S, Will C, et al. CNNM2, encoding a basolateral protein required for renal Mg2+ handling, is mutated in dominant hypomagnesemia. Am J Hum Genet 2011; 88:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/18\">",
"      Dai LJ, Friedman PA, Quamme GA. Cellular mechanisms of chlorothiazide and cellular potassium depletion on Mg2+ uptake in mouse distal convoluted tubule cells. Kidney Int 1997; 51:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/19\">",
"      Kroenke K, Wood DR, Hanley JF. The value of serum magnesium determination in hypertensive patients receiving diuretics. Arch Intern Med 1987; 147:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/20\">",
"      Groenestege WM, Th&eacute;bault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/21\">",
"      Fakih M. Anti-EGFR monoclonal antibody-induced hypomagnesaemia. Lancet Oncol 2007; 8:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/22\">",
"      Dai LJ, Quamme GA. Intracellular Mg2+ and magnesium depletion in isolated renal thick ascending limb cells. J Clin Invest 1991; 88:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/470/abstract/23\">",
"      Shils ME. Experimental human magnesium depletion. Medicine (Baltimore) 1969; 48:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 844 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_470=[""].join("\n");
var outline_f0_29_470=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UNITS OF MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RENAL HANDLING OF MAGNESIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Loop of Henle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Distal reabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REGULATION OF PLASMA MAGNESIUM CONCENTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CELLULAR MAGNESIUM STORES AND CYTOSOLIC MAGNESIUM ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/844\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/844|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/62/31725\" title=\"figure 1\">",
"      Loop of Henle transport",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=related_link\">",
"      Causes and treatment of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=related_link\">",
"      Diuretics and magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_29_471="The use of chromones (cromoglycates) in the treatment of asthma";
var content_f0_29_471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The use of chromones (cromoglycates) in the treatment of asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/471/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/471/contributors\">",
"     James P Kemp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/471/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/471/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/471/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/471/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/29/471/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    (or cromolyn) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    , are commonly grouped together as chromones (also called cromoglycates). Strictly speaking, cromolyn is a chromone, whereas nedocromil belongs to the structural class of pyranoquinolines. Both agents contain a chromone ring configuration (one ring in nedocromil, two in cromolyn) and they share many clinical characteristics.",
"   </p>",
"   <p>",
"    Cromolyn was first introduced in Great Britain in the early 1970s for severe allergic asthma. Since then, recommendations for its use have shifted to milder asthma, where the agent gained greater acceptance. The chromones are currently listed as alternate initial controller therapies for mild asthma in national and international guidelines, although inhaled glucocorticoids (GCs) (also known as inhaled corticosteroids) are the preferred agents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The low incidence of side effects compared to inhaled GCs is a leading reason some patients prefer chromones over inhaled GCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIMITATIONS ON AVAILABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of cromoglycates varies from one country to another, due in part to the need to change the propellants used in cromoglycate metered dose inhalers (MDIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The propellant originally had been a chlorofluorocarbon (CFC). Following adoption of the Montreal protocol (an international agreement to ban CFCs), inhalers that contain hydrofluoroalkane (HFA) were developed for some drugs. HFA formulations of cromolyn are available in the United Kingdom and a Spinhaler device is available in Australia, although neither of these is sold in the US. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, neither cromolyn nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    is available in HFA-containing (MDIs), and no formulation of nedocromil is currently marketed for asthma. As a result, the only remaining formulations for asthma are solutions of cromolyn (10",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    for nebulization. However, dry powder inhaler formulations for cromolyn and nedocromil are available in other countries (",
"    <a class=\"graphic graphic_table graphicRef56418 \" href=\"UTD.htm?32/17/33052\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chromones have potent effects in preventing both early and late asthmatic responses to inhaled allergens, such as pollen, and reducing airway reactivity to a range of inhaled irritants, such as sulfur dioxide and cold air [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothesis proposed to explain the mechanism of action of the chromones involves two related and possibly sequential processes, which act to stabilize airway mast cells and perhaps other inflammatory cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, the drugs cause phosphorylation of a cell membrane moesin-like protein that is responsible for the termination of mediator release from mast cells and probably a broad range of other cells responsible for allergic inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/6\">",
"       6",
"      </a>",
"      ]. As such, chromones appear to activate a natural \"turn-off switch\" in the very early stages of an asthmatic response to an external noxious stimulus. This action may explain the ability of cromolyn to block the acute bronchospastic response to inhaled antigen equally effectively whether administered one minute or one hour prior to challenge [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Second, chromones inhibit the activation of a chloride current in cells undergoing shape and volume changes associated with cell activation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/8\">",
"       8",
"      </a>",
"      ]. The opening of chloride channels is followed by opening of calcium channels and degranulation; chromones affect only the chloride channels [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other putative mechanisms have been proposed, including inhibition of the synthesis of IgE antibody by B-lymphocytes and a gradual reduction in airway hyperreactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Cromolyn may also prevent lung damage by acting as an oxygen free radical scavenger [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both medications are potent G protein coupled receptor 35 (GPR 35) agonists. GPR 35 is up regulated upon challenge with IgE antibody and is expressed in mast cells basophils and eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ROLE IN ASTHMA THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chromones have clinical utility in two distinct clinical situations: prophylactic use before exposure to a known asthma trigger and chronic use as a controller therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevention of acute bronchoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single treatment (one nebulized 20 mg dose of cromolyn or two or more puffs of either cromolyn or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    from a metered dose inhaler (MDI)) administered 10 to 15 minutes before an anticipated trigger exposure (ie, exercise, pollen, animals) is usually sufficient to provide protection. For protection against stronger challenges or in more sensitive patients, inhaled beta agonists may be administered immediately prior to the chromone because the combination is additive in benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .) We know of no studies that compared the chromones to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    directly for the prevention of bronchoconstriction.",
"   </p>",
"   <p>",
"    Cromolyn was originally introduced in Europe and later in the United States primarily for the prevention of allergic asthma (the trade name Intal was a contraction of \"interferes with allergy\"). The early emphasis on an allergic diathesis and the restriction of its use to the most severe asthmatics led to initial clinical confusion and disappointment. Subsequent analyses directed clinical usage toward those with milder asthma and nonallergic as well as allergic precipitants for their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chromones can be used to prevent bronchoconstriction, although they do not have bronchodilating properties for relief of acute symptoms, unlike the short-acting beta agonists. It is therefore important to insure that patients understand that beta agonists should be used instead for rapid relief of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Efficacy as long-term maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chromones may also be used as antiinflammatory controller agents. The clinical efficacy of cromolyn and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    is similar. Inhaled GCs are the preferred initial antiinflammatory therapy for patients of all ages with mild persistent asthma, as mentioned previously. However, the chromones are considered alternative first line agents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/1,2,11,16,17\">",
"     1,2,11,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18154?source=see_link\">",
"     \"Treatment of intermittent and mild persistent asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2006 systematic review examined trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    to placebo in the management of chronic asthma in children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/18\">",
"     18",
"    </a>",
"    ]. Fifteen trials including 1422 children were included, most of whom had mild or moderate persistent asthma. The primary outcome was an improvement in symptom-free days. Short term studies (one to three months) showed some improvements in lung function with nedocromil. Two longer-term studies (one of six-months duration, and another of four to six years duration) found variable improvement in symptom free days and some improvement in lung function parameters. Overall, these findings suggested mild efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Compared to inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies concluded that the chromones were less effective than inhaled GCs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/16,19,20\">",
"     16,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study compared risk of hospitalization for asthma with use of asthma medications in an analysis of 16,941 eligible adults and children in a managed health care setting [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/16\">",
"       16",
"      </a>",
"      ]. The relative risk of hospitalization among those who received cromolyn was most reduced among children (RR=0.8; 95% confidence interval [CI], 0.7-0.9), although the reduction in risk was greater for those given inhaled GCs (RR=0.5; 95% CI, 0.4-0.6) after adjustment for beta agonist dispensing.",
"     </li>",
"     <li>",
"      A trial of 1041 children with mild to moderate asthma, aged 5 to 12 years, randomized subjects to inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"       nedocromil",
"      </a>",
"      (8 mg twice daily), inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (200 mcg twice daily), or placebo, and followed the children for four to six years [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/19\">",
"       19",
"      </a>",
"      ]. Both active treatments reduced the number of urgent care visits and the frequency of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      use, although the effect was greater with budesonide (12 versus 16 visits per 100-person years). Budesonide resulted in improved airway hyperresponsiveness and a smaller decrement in lung function, effects which were not seen with nedocromil.",
"     </li>",
"     <li>",
"      A 2006 meta-analysis of 25 randomized, controlled trials (1600 adults and children) compared cromolyn and inhaled GCs [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/20\">",
"       20",
"      </a>",
"      ]. Inhaled GCs were more effective at improving lung function and asthma control.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Compared to other controller agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;One 12 week, open-label study randomized 333 children aged 6 to 11 with mild to moderate asthma to either one month of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    (5 mg daily) or one month of cromolyn (two puffs four times daily), with crossing over to the other treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/21\">",
"     21",
"    </a>",
"    ]. Daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    use was reduced by 38 percent and 23 percent by montelukast and cromolyn, respectively. Parents and patients both preferred and were more compliant with montelukast. However, the brief duration of therapy in this study may have prevented patients from benefiting maximally from the cromolyn, as the chromones require one to three months to reach full efficacy. Further direct comparative trials are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial trial of a cromolyn or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    should be one to three months in duration in order to attain full efficacy. Because chromones act solely to prevent bronchospasm and do not have acute bronchodilating capacity, some clinicians initiate therapy concomitantly with a short course of oral glucocorticoids to maximize lung function before relying on the chromone alone. This is particularly helpful for patients with excessive bronchial constriction, who may have initial difficulty inhaling medications. All patients should also have access to a short-acting beta-2 agonist, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    , for relief of acute symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience has favored the use of cromolyn in younger children and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    in adolescents and adults. Nedocromil generally has displayed greater potency in protecting patients against nonimmunologic stimuli and is a broader spectrum antiinflammatory agent than cromolyn [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/22\">",
"     22",
"    </a>",
"    ]. However, nedocromil is no longer available in the United States.",
"   </p>",
"   <p>",
"    Circumstances that might favor the choice of cromolyn (over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    ) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild asthma with allergic triggers; cromolyn is better studied in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When a nebulized chromone formulation is preferred, as in asthmatics younger than five years of age. Only cromolyn is available in a solution for nebulization.",
"     </li>",
"     <li>",
"      In asthmatics who object to the taste of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"       nedocromil",
"      </a>",
"      (approximately one in eight patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Circumstances that favor the choice of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    (over cromolyn) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less adherent patients in whom the initial twice daily dosage of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"       nedocromil",
"      </a>",
"      provides a decided advantage.",
"     </li>",
"     <li>",
"      Patients already receiving an inhaled GC, because",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"       nedocromil",
"      </a>",
"      appears to have a more potent steroid-sparing effect than cromolyn [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/24-26\">",
"       24-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initial dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximal dose is usually used initially. After one to three months, this can be reduced to the lowest effective dose. Standard doses are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef56418 \" href=\"UTD.htm?32/17/33052\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cromolyn",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shift in the recommended use of chromones from severe to mild asthma has been paralleled by a reduction in dosage in available formulations. Cromolyn in a MDI provides a dose of 800 mcg per actuation, whereas the original formulation (a dry powder inhaler) delivered 20 mg per dose. The change in formulation may alter the generalizability of the earlier studies to current use, as the lower MDI dose may not deliver the same level of clinical efficacy in severe asthma as was demonstrated with the original 20 mg formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/17\">",
"     17",
"    </a>",
"    ]. The 20 mg dose is currently only available in a solution for nebulization. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Limitations on availability'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cromolyn was administered by MDI at a dose of two to four inhalations, three to four times daily initially. Cromolyn has been safely administered by inhalation in doses up to 80 mg per day (via nebulization).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nedocromil",
"    </span>",
"    &nbsp;&mdash;&nbsp;HFA-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    inhalers should deliver approximately 2 mg per actuation. The usual dose is two to four puffs twice daily; up to four puffs four times daily may be used in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/471/abstract/27\">",
"     27",
"    </a>",
"    ]. Nedocromil-HFA is not available in the United States, as mentioned previously. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Limitations on availability'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both cromolyn and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    have remarkably favorable therapeutic indices and appear to have minimal systemic absorption after inhalation. Mild, local throat irritation and cough may occur. There is no known toxicity from chromone overdosage, and there are no known adverse drug interactions. Both drugs carry a category B pregnancy rating (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Idiosyncratic systemic reactions, such as myositis, anaphylactoid reactions, eosinophilic pneumonia, and acute bronchospasm have been reported, but such events appear to be extremely rare.",
"   </p>",
"   <p>",
"    The favorable side effect profile of the chromones is a major factor in their selection versus inhaled glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , and long-acting beta agonists. However, antileukotriene agents are also generally well tolerated and can be administered orally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=see_link\">",
"     \"Theophylline use in asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled cromolyn and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    act by preventing both early and late asthmatic responses to inhaled allergens and irritants, such as exercise and cold air. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Pharmacology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These agents can be administered prophylactically 10 to 15 minutes before exposure to a known asthma trigger. They do not have acute bronchodilatory properties, unlike short-acting beta agonists. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Role in asthma therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chromones can also be administered regularly as antiinflammatory controller therapy in mild persistent asthma. National and international guidelines, however, recommend inhaled glucocorticoids rather than chromones as the preferred initial controller therapy in patients of all ages (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Efficacy as long-term maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chromones, although less effective than inhaled glucocorticoids, are virtually devoid of systemic side effects; they may be desirable alternative or additive controller agents in young children or patients who don't tolerate or don't wish to take inhaled glucocorticoids. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Compared to inhaled glucocorticoids'",
"      </a>",
"      above.) Asthma is being increasingly recognized as a heterogenous disorder, and it is important to look for individual responses to medications that can be greater than the mean response in a given patient population.",
"     </li>",
"     <li>",
"      The efficacy of the chromones has not been compared to that of the antileukotriene agents or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Compared to other controller agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An initial trial of cromolyn or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"       nedocromil",
"      </a>",
"      for control of asthma should be one to three months in duration. The maximal dose is given initially, and then tapered to the lowest effective dose. Significant adverse reactions are rare with both medications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).",
"    </li>",
"    <li>",
"     Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. www.ginasthma.org (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/3\">",
"      Netzer NC, K&uuml;pper T, Voss HW, Eliasson AH. The actual role of sodium cromoglycate in the treatment of asthma--a critical review. Sleep Breath 2012; 16:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/4\">",
"      Keller M, Schierholz J. Have inadequate delivery systems hampered the clinical success of inhaled disodium cromoglycate? Time for reconsideration. Expert Opin Drug Deliv 2011; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     Holgate ST, Edwards AM. The chromones: Cromolyn sodium and nedocromil sodium. In: Middleton's allergy: Principles and practice, 6th ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis 2003. p.915.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/6\">",
"      Correia I, Wang L, Pang X, Theoharides TC. Characterization of the 78 kDa mast cell protein phosphorylated by the antiallergic drug cromolyn and homology to moesin. Biochem Pharmacol 1996; 52:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/7\">",
"      Altounyan RE, Howell JB. Treatment of asthma with disodium cromoglycate (FPL 670, 'Intal'). Respiration 1969; 26:Suppl:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/8\">",
"      Heinke S, Sz&uuml;cs G, Norris A, et al. Inhibition of volume-activated chloride currents in endothelial cells by chromones. Br J Pharmacol 1995; 115:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/9\">",
"      Mazurek N, Schindler H, Sch&uuml;rholz T, Pecht I. The cromolyn binding protein constitutes the Ca2+ channel of basophils opening upon immunological stimulus. Proc Natl Acad Sci U S A 1984; 81:6841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/10\">",
"      Loh RK, Jabara HH, Geha RS. Disodium cromoglycate inhibits S mu--&gt;S epsilon deletional switch recombination and IgE synthesis in human B cells. J Exp Med 1994; 180:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/11\">",
"      Hoag JE, McFadden ER Jr. Long-term effect of cromolyn sodium on nonspecific bronchial hyperresponsiveness: a review. Ann Allergy 1991; 66:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/12\">",
"      Sadeghi-Hashjin G, Nijkamp FP, Henricks PA, Folkerts G. Sodium cromoglycate and doxantrazole are oxygen radical scavengers. Eur Respir J 2002; 20:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/13\">",
"      Yang Y, Lu JY, Wu X, et al. G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 2010; 86:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/14\">",
"      Latimer KM, O'Byrne PM, Morris MM, et al. Bronchoconstriction stimulated by airway cooling. Better protection with combined inhalation of terbutaline sulphate and cromolyn sodium than with either alone. Am Rev Respir Dis 1983; 128:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/15\">",
"      Toogood JH, Lefcoe NM, Wonnacott TM, et al. Cromolyn sodium therapy: Predictors of response. Adv Asthma Allergy Pulm Dis 1978; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/16\">",
"      Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/17\">",
"      Bernstein IL, Siegel SC, Brandon ML, et al. A controlled study of cromolyn sodium sponsored by the Drug Committee of the American Academy of Allergy. J Allergy Clin Immunol 1972; 50:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/18\">",
"      Sridhar AV, McKean M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev 2006; :CD004108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/19\">",
"      Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/20\">",
"      Guevara JP, Ducharme FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006; :CD003558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/21\">",
"      Bukstein DA, Bratton DL, Firriolo KM, et al. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma 2003; 40:475.",
"     </a>",
"    </li>",
"    <li>",
"     Woolcock AJ. Treatment of asthma. In: Asthma and rhinitis, Busse WW, Holgate ST (Eds), Blackwell Scientific Publications, Boston and Oxford 1995. p.1364.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/23\">",
"      Grigg CF. Responders and nonresponders to cromolyn sodium. Current Issues in Resp Med 1998; 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/24\">",
"      K&ouml;nig P, Grigg CF. Cromolyn sodium or nedocromil in childhood asthma: does it matter? Clin Exp Allergy 2000; 30:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/25\">",
"      Marin JM, Carrizo SJ, Garcia R, Ejea MV. Effects of nedocromil sodium in steroid-resistant asthma: a randomized controlled trial. J Allergy Clin Immunol 1996; 97:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/26\">",
"      Svendsen UG, J&oslash;rgensen H. Inhaled nedocromil sodium as additional treatment to high dose inhaled corticosteroids in the management of bronchial asthma. Eur Respir J 1991; 4:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/471/abstract/27\">",
"      Holgate ST. The efficacy and therapeutic position of nedocromil sodium. Respir Med 1996; 90:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 531 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-D41C5C4F74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_471=[""].join("\n");
var outline_f0_29_471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIMITATIONS ON AVAILABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ROLE IN ASTHMA THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevention of acute bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Efficacy as long-term maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Compared to inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Compared to other controller agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initial dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cromolyn",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nedocromil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/531\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/531|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/17/33052\" title=\"table 1\">",
"      Dosing of cromolyn sodium and nedocromil in asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18154?source=related_link\">",
"      Treatment of intermittent and mild persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_29_472="Fentanyl: Patient drug information";
var content_f0_29_472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fentanyl: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     see \"Fentanyl: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"     see \"Fentanyl: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Abstral&reg;;",
"     </li>",
"     <li>",
"      Actiq&reg;;",
"     </li>",
"     <li>",
"      Duragesic&reg;;",
"     </li>",
"     <li>",
"      Fentora&reg;;",
"     </li>",
"     <li>",
"      Lazanda&reg;;",
"     </li>",
"     <li>",
"      Onsolis&reg;;",
"     </li>",
"     <li>",
"      Subsys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abstral&trade;;",
"     </li>",
"     <li>",
"      Actiq&reg;;",
"     </li>",
"     <li>",
"      Apo-Fentanyl&reg; Matrix;",
"     </li>",
"     <li>",
"      Duragesic&reg;;",
"     </li>",
"     <li>",
"      Duragesic&reg; MAT;",
"     </li>",
"     <li>",
"      Fentanyl Citrate Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Fentanyl;",
"     </li>",
"     <li>",
"      Onsolis&reg;;",
"     </li>",
"     <li>",
"      PMS-Fentanyl MTX;",
"     </li>",
"     <li>",
"      RAN&trade;-Fentanyl Matrix Patch;",
"     </li>",
"     <li>",
"      RAN&trade;-Fentanyl Transdermal System;",
"     </li>",
"     <li>",
"      ratio-Fentanyl;",
"     </li>",
"     <li>",
"      Sandoz Fentanyl Patch;",
"     </li>",
"     <li>",
"      Teva-Fentanyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be watched closely to make sure you do not misuse, abuse, or become addicted to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This warning is for Fentora&reg;, lozenges (eg, Actiq&reg;), Lazanda&reg;, Abstral&reg;, Subsys&reg;, or Onsolis&reg; only. It is for cancer pain that is poorly treated by other pain drugs. It is not to be used for pain caused by surgery. Keep away from children. Do not use in children. It may slow down breathing too much if not used the right way. You may only get these products from the TIRF REMS Access program.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700897",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This warning is for the skin patch only. It is only used to treat lasting, long-term pain that cannot be helped by other drugs. It is only for use in patients who already take opioids (such as morphine, oxycodone, or hydromorphone) and are use to them. It is not for mild pain or pain that comes and goes. It is not for use in children younger than 2 years of age. Do not use a cut patch or one that does not look right.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fentanyl or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, bowel block, or very bad lung disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696692",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid use of heat sources (such as sunlamps, tanning beds, heating pads, electric blankets, heat lamps, saunas, hot tubs, heated waterbeds). Avoid long, hot baths or sunbathing. Your temperature may rise and cause too much drug to pass into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever may cause too much drug to pass into your body. Call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The patch may have metal. Take off the patch before an MRI.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3734030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <span style=\"text-decoration: underline\">",
"        <b>",
"         Under the tongue (sublingual) spray:",
"        </b>",
"       </span>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3734082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If have sores in your mouth, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing. Slow breathing, shallow breathing, or trouble breathing are all signs of this. Call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If anyone else takes your drugs or touches your patch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698713",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using the patch and have a fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use patches that are cut or do not look right.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you or anyone else touches the gel, wash the skin with lots of water. Do not use soap.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4044828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You do not need to put the patch on or near where you are having pain for it to work.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take off old patch first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on clean, dry, healthy skin on the chest, back, upper leg, or upper arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4044855",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put the patch on the belt line, bra line, or skin folds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clip hair at site before putting patch on. Do not shave.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695471",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the patch site with each patch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bathe, shower, or swim for short periods after putting on the patch. Cover the patch with plastic wrap and tape to help keep it in place.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the patch falls off, put a new one on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3688608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the patch loosens, put tape ONLY on the edges of the patch to hold it in place.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Lozenge:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place lozenge in your mouth between the cheek and lower gum.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695691",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Suck oral lozenge. Do not chew, break, or crush it. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696397",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cheek film:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet the inside of your cheek with your tongue or water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place the film inside your mouth on a wet cheek. Hold for 5 seconds so it sticks to the cheek. Let it melt.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew or swallow.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may drink liquids 5 minutes after using.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may eat after film melts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cheek tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695523",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place tablet in your mouth above a rear molar tooth between the upper cheek and gum and let melt.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3533623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prime pump by spraying it 4 times into the supplied pouch. A green bar will show when it is ready to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Close 1 nostril.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3533624",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put spray",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       inch into nostril. Press down on finger grip. A click will sound letting you know the dose was given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3734030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <span style=\"text-decoration: underline\">",
"        <b>",
"         Under the tongue (sublingual) spray:",
"        </b>",
"       </span>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3734031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray into the mouth under the tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2893560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         <b>",
"          Under the tongue (sublingual) tablet:",
"         </b>",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3370402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place under tongue and let melt all the way. Do not chew, suck or swallow tablet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3370403",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat or drink until tablet has melted all the way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3370404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may wet your mouth with water, if needed, before you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use Fentora&reg; tablets right after opening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use Onsolis&trade; film right after opening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3370407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use Abstral&reg; tablets right after opening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3734030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <span style=\"text-decoration: underline\">",
"        <b>",
"         Under the tongue (sublingual) spray:",
"        </b>",
"       </span>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use right after opening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3734034",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put used spray into the small throw away bag that comes with this drug. Seal bag and throw away in the trash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3734035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If any sprays are not used and are not needed anymore, drain the drug into the bottle that comes with this drug. Place the bottle into the large throw away bag, seal the bag, and then throw away in the trash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705500",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699145",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After you take off a skin patch, be sure to fold the sticky sides of the patch to each other.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away unused patches when they are no longer needed by flushing down a toilet or sink. Take them from the pouch, take off liner, and fold in half.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3533626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray any left over drug from the bottle into the supplied pouch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3533627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drained bottle and sealed pouch inside the supplied child resistant holder.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3533628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put cap on the holder and twist to lock.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3533629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away holder in the trash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12468 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_472=[""].join("\n");
var outline_f0_29_472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170610\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022833\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022835\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022834\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022839\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022840\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022842\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022837\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022838\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022843\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022844\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=related_link\">",
"      Fentanyl: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=related_link\">",
"      Fentanyl: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_29_473="Endoscopy snare billie club";
var content_f0_29_473=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Endoscopic view and snare of the Billie club",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 513px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A polypectomy snare is deployed around the Billie club and gentle traction under direct visualization is used to guide the foreign body toward the rectum for transanal extraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Justin A Maykel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_473=[""].join("\n");
var outline_f0_29_473=null;
var title_f0_29_474="Methamphetamine intoxication";
var content_f0_29_474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Methamphetamine intoxication",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/474/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/474/contributors\">",
"     Edward W Boyer, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/474/contributors\">",
"     Christina Hernon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/474/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/474/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/474/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/29/474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/29/474/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/29/474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine is a sympathomimetic amine that belongs to a class of compounds, the phenethylamines, with a variety of stimulant, anorexiant, euphoric, and hallucinogenic effects. Methamphetamine was first synthesized in 1893. Thirty years later, pharmaceutical formulations were introduced as treatments for nasal congestion and asthma. Methamphetamine was widely used by German, Japanese, and American forces during World War II to increase alertness and decrease fatigue.",
"   </p>",
"   <p>",
"    Methamphetamine is used clinically for treatment of attention deficit disorder with hyperactivity (ADHD), short-term treatment of obesity, and as an off-label treatment for narcolepsy. Recreational use of methamphetamine and other amphetamine-derived stimulants has reached epidemic proportions in the United States (US), southern Asia, the Philippines, and Japan. After cannabis, it is the most widely abused drug worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 5 percent of the US population has used methamphetamine, with an estimated 500,000 people using the drug in a given month. [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methamphetamine may be synthesized via simple reactions using readily available chemicals and over-the-counter cold medicines, such as ephedrine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    . Although some illicit methamphetamine is diverted pharmaceutical product, the majority of recreational methamphetamine is manufactured specifically for illicit use. The output of thousands of small laboratories in predominantly rural regions of the US has been supplanted by \"superlabs\" whose output is kilogram quantities. Clandestine methamphetamine synthesis carries significant risk of explosion or toxic exposure and is responsible for exposing many children to profoundly toxic products [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the toxicology, diagnosis, and management of acute methamphetamine intoxication. The general management of acute drug overdose and the management of other stimulants, such as cocaine, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenethylamines comprise a class of central nervous system (CNS) stimulants (",
"    <a class=\"graphic graphic_figure graphicRef81133 \" href=\"UTD.htm?41/4/42060\">",
"     figure 1",
"    </a>",
"    ). Various substitutions on the basic phenethylamine structure determine the degree of CNS penetration, likelihood of degradation by monoamine oxidase (MAO), receptor binding affinity, and the range of effects.",
"   </p>",
"   <p>",
"    The prototypical phenylethylamine is alpha methyl phenethylamine, which is contracted to give the common name amphetamine. Amphetamine possesses a methyl group at the alpha position of the carbon chain (",
"    <a class=\"graphic graphic_figure graphicRef81153 \" href=\"UTD.htm?8/32/8717\">",
"     figure 2",
"    </a>",
"    ). Methamphetamine has a second methyl group (",
"    <a class=\"graphic graphic_figure graphicRef81294 \" href=\"UTD.htm?28/46/29420\">",
"     figure 3",
"    </a>",
"    ), which increases lipophilicity and CNS activity. Methamphetamine exists in dextro- or levo- stereoisomers, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    analogues conferring greater CNS stimulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Methamphetamine-neurotransmitter interactions",
"      </strong>",
"      &ndash; The neurotransmitters norepinephrine, epinephrine, and serotonin are stored within cytoplasmic vesicles of presynaptic adrenergic neurons. These neurotransmitters are released into the synapse with nerve depolarization. Once in the synapse, the neurotransmitters bind to postsynaptic receptors and elicit neurochemical responses. Thereafter, they diffuse away from the postsynaptic receptor and are quickly degraded or undergo cellular reuptake and replaced into vesicles. Reuptake is mediated through adenosine triphosphate (ATP)-dependent or ion-dependent (Na+) neurotransmitter transporters, as well as by concentration gradient channels.",
"      <br/>",
"      <br/>",
"      Methamphetamine lacks direct adrenergic effects, but is instead an indirect neurotransmitter. Methamphetamine is incorporated into cytoplasmic vesicles where it displaces epinephrine, norepinephrine, dopamine, and serotonin into the cytosol. As cytosolic concentrations rise, neurotransmitters diffuse out of the neuron and into the synapse where they activate postsynaptic receptors. Methamphetamine also inactivates neurotransmitter reuptake transporter systems.",
"      <br/>",
"      <br/>",
"      The result of these two processes is a surge of adrenergic stimulation. The lone modulatory response to such stimulation is degradation by catechol o-methyl transferase (COMT), a slow, saturable degradation pathway.",
"      <br/>",
"      <br/>",
"      Stimulated alpha- and beta-adrenergic receptors produce hypertension, tachycardia, hyperthermia, and vasospasm. Serotonergic activation contributes to alterations in mood as well as deranged responses to hunger and thirst. Dopamine receptor stimulation affects drug-craving and drug-seeking behavior, and psychiatric symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS AND METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine is readily absorbed following administration via oral, pulmonary, nasal, intramuscular, intravenous, rectal, and vaginal routes. Body stuffing has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methamphetamine is lipophilic, readily crosses the blood-brain barrier, and has a large volume of distribution (3 to 4",
"    <span class=\"nowrap\">",
"     L/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/10\">",
"     10",
"    </a>",
"    ]. Onset of action occurs within seconds after smoking or injection; effects may be observed within 5 minutes after intranasal use or within 20 minutes following oral ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/11\">",
"     11",
"    </a>",
"    ]. Peak plasma concentrations are achieved approximately 30 minutes following intravenous or intramuscular administration and up to 2 to 3 hours after ingestion. Although methamphetamine has a plasma half-life of 12 to 34 hours, the duration of its effect commonly persists beyond 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elimination of methamphetamine occurs via several hepatic and renal pathways, including cytochrome CYP2D6. Polymorphisms of this cytochrome isoform have been implicated in cases of unanticipated toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/11\">",
"     11",
"    </a>",
"    ]. Enzymatic degradation of methamphetamine results in active metabolites which may accumulate with repeated, frequent, or binge use. Renal elimination that is dependent upon urinary pH is related to methamphetamine's alkaline pKa of 9 to 10.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should consider the diagnosis of methamphetamine intoxication in any diaphoretic patient with hypertension, tachycardia, severe agitation, and psychosis. Acutely intoxicated patients may become extremely agitated and pose a danger to themselves, other patients, and medical staff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are unable to provide any history because of severe agitation. If possible, clinicians should identify the route of exposure to methamphetamine and the frequency of use, which can help distinguish among short-term, binge, and chronic abuse. Ascertaining the potential amounts of methamphetamine ingested, as well as the use of other illicit substances and coingestants (eg, heroin, benzodiazepines), can guide therapeutic interventions.",
"   </p>",
"   <p>",
"    In body stuffers (individuals who ingest methamphetamine to avoid arrest) and body packers (individuals who internally conceal large volumes of drug for transport), special attention should be paid to the heart rate and temperature. According to at least two case series, methamphetamine body stuffers who present with a heart rate above 120 beats per minute or a temperature over 38&deg;C are at greater risk of severe outcomes (including: seizures, altered mental status requiring intubation, creatine kinase &gt;50,000",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    increased troponin, liver transaminase increase &gt;1000",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and death). The number of packets ingested, their size, the wrapping used, the time from ingestion, and abdominal complaints (eg, constipation, obstipation, distention, and vomiting) do not correlate as closely with severe morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Methamphetamine can cause a host of respiratory, cardiac, vascular, otolaryngologic, neurologic, integumentary, psychiatric, infectious, traumatic, and dental maladies; when possible, a thorough review of systems is in order.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with methamphetamine intoxication range from the virtually asymptomatic to those in sympathomimetic crisis with seizures, metabolic acidosis, and imminent cardiovascular collapse. Agitation, tachycardia, and psychosis are among the most frequent findings identified on presentation to the emergency department (ED) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Life-threatening intoxication is characterized by hypertension, tachycardia, severely agitated delirium, hyperthermia, metabolic acidosis, and seizures. Prognostic factors for mortality include: coma, shock, body temperature &gt;39&ordm;C, acute renal failure, metabolic acidosis, and hyperkalemia (K 5.6 to 8.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       General appearance",
"      </strong>",
"      &ndash; Methamphetamine abusers may appear malnourished, agitated, and disheveled [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/17\">",
"       17",
"      </a>",
"      ]. Hypervigilance and akathisia may be present in mildly intoxicated patients, while patients with severe intoxication may exhibit abrupt changes in behavior, becoming extraordinarily violent. Excoriations on the skin and track marks suggest prolonged and intravenous use, respectively. Profound diaphoresis is common in moderate to severe intoxication. Look carefully for stigmata of trauma, which is common among methamphetamine abusers [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Vital signs",
"      </strong>",
"      &ndash; The severity of patient agitation sometimes prevents measurement of vital signs. Methamphetamine produces dose-dependent variations of pulse and blood pressure. At low doses (10 to 25 mg), elevations in heart rate and blood pressure may be insignificant [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/20\">",
"       20",
"      </a>",
"      ]. At higher doses (30 to 40 mg), sympathomimetic stimulation may produce dramatic increases in heart rate, blood pressure, and respiratory rate [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/20\">",
"       20",
"      </a>",
"      ]. Elevated temperature is common in moderate to severe intoxication while hypertensive crisis, hyperthermia, and refractory tachydysrhythmias are associated with severe intoxication.",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiovascular",
"      </strong>",
"      &ndash; Tachycardia and hypertension are nearly universal among intoxicated patients irrespective of severity. Cardiac ischemia, myocardial infarction, and cardiomyopathy have been identified in acute and chronic users. In a retrospective, observational study of methamphetamine-exposed patients who presented to the emergency department complaining of chest pain, 25 percent had evidence of an acute coronary syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Severe methamphetamine intoxication is associated with sudden cardiovascular collapse, particularly in agitated patients who are physically restrained to prevent injury to themselves and others, including law enforcement and clinicians. Severe agitation often presages cardiac arrest, which can occur with frightening rapidity, and has been observed after only a few minutes' struggle.",
"      <br/>",
"      <br/>",
"      Cardiovascular collapse is postulated to arise from a combination of neurotransmitter depletion, metabolic acidosis, and dehydration. In 2009, the Unites States&rsquo; National Poison Data System reported 2183 methamphetamine exposures involving consultation with the Poison Control Center System. There were seven deaths and 384 life-threatening events [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/22\">",
"       22",
"      </a>",
"      ]. These figures likely underestimate the number of severe exposures, due to under-reporting.",
"      <br/>",
"      <br/>",
"      Valvular dysfunction may be related to the serotonergic effects of methamphetamine, while aortic dissection and rupture are more likely due to its vasospastic and hypertensive effects. Injection drug use increases the risk of infectious sequelae, such as bacterial endocarditis.",
"     </li>",
"     <li>",
"      <strong>",
"       Head, eyes, ears, nose and throat (HEENT)",
"      </strong>",
"      &ndash; Common HEENT examination findings include minimally reactive mydriasis, mucosal injuries from insufflation (snorting), oropharyngeal burns in methamphetamine smokers, and gingival hypertrophy. Those involved in methamphetamine production are at risk for burn and inhalation injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Extensive tooth decay (\"meth-mouth\") is common in chronic methamphetamine abuse due to bruxism, decreased saliva production, and poor dental hygiene (",
"      <a class=\"graphic graphic_picture graphicRef80482 \" href=\"UTD.htm?35/26/36260\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary",
"      </strong>",
"      &ndash; Increases in minute ventilation, respiratory rate, and tidal volume are often associated with severe intoxication. Illicit methamphetamine may contain pulmonary irritants that are directly toxic to the lung. Methamphetamine has been implicated in acute pulmonary edema [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/25\">",
"       25",
"      </a>",
"      ], pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/26,27\">",
"       26,27",
"      </a>",
"      ], and, if smoked, thermal injury. Other pulmonary complications include: pneumothorax, pneumomediastinum, pneumonia, acute lung injury, and pulmonary hemorrhage. Similar injuries have been seen after inhalation of heroin and smoked cocaine (crack) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=see_link\">",
"       \"Pulmonary complications of cocaine abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Gastrointestinal",
"      </strong>",
"      &ndash; Methamphetamine can induce vomiting and diarrhea due to sympathomimetic stimulatory effects. Severe abdominal pain out of proportion to physical examination findings suggests methamphetamine-associated bowel ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/29\">",
"       29",
"      </a>",
"      ], particularly in the setting of body packing and stuffing. Rectal exposure to methamphetamine occurs in cases of transport for distribution (ie, body packing) and rectal administration (\"booty bumping\") [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"       \"Internal concealment of drugs of abuse (body packing)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Gynecologic/obstetric",
"       </strong>",
"      </span>",
"      &ndash; Vaginal exposure to methamphetamine arises from body stuffing, body packing, or vaginal administration of the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/9\">",
"       9",
"      </a>",
"      ]. Among pregnant abusers, placental insufficiency, hemorrhage, and abruption are reported [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Extremities",
"      </strong>",
"      &ndash; The extremities are a likely site of injury from burns or trauma, and stigmata of repeated intravenous injection (track marks) may be present.",
"     </li>",
"     <li>",
"      <strong>",
"       Dermatologic",
"      </strong>",
"      &ndash; Drug preparation may cause thermal or chemical burns, most commonly to the hands and face [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Injection drug use may produce cellulitis, abscesses, and track marks (",
"      <a class=\"graphic graphic_picture graphicRef86745 \" href=\"UTD.htm?6/21/6482\">",
"       picture 2",
"      </a>",
"      ). Protracted methamphetamine abuse is associated with formication (\"crank bugs,\" a feeling that ants are crawling on the skin), and many methamphetamine abusers suffer multiple small skin excoriations from unremitting picking (",
"      <a class=\"graphic graphic_picture graphicRef86746 \" href=\"UTD.htm?5/44/5829\">",
"       picture 3",
"      </a>",
"      ). Jaundice may be due to hepatitis, while poor nutrition and vitamin deficiencies may cause skin changes (cracking, angular cheilitis, aphthous ulcers) or abdominal bleeding and bruising.",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic",
"      </strong>",
"      &ndash; Choreiform movement disorders are a relatively common finding in acute methamphetamine intoxication, and arise from derangements in dopaminergic neurotransmission [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/31\">",
"       31",
"      </a>",
"      ]. Focal neurologic deficits may represent central nervous system ischemia, infarction, or hemorrhage. Seizures are associated with severe intoxication, typically within 24 hours of methamphetamine use. They are usually self-limited and brief [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Psychiatric",
"      </strong>",
"      &ndash; Acute methamphetamine use can induce agitated delirium and paranoia. Binge or chronic methamphetamine use is strongly associated with a variety of psychiatric symptoms, including paranoia and psychosis, but delusions, homicidal and suicidal ideation, mood disturbance, anxiety, and hallucinations also occur [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/34\">",
"       34",
"      </a>",
"      ]. Suicidality, homicidality, psychosis, and abnormal behavior and movements are commonly seen in binge as well as chronic users. Psychiatric symptoms are often the chief complaint of patients presenting to the emergency or acute care setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the diagnosis of methamphetamine intoxication requires recognition of the sympathomimetic toxidrome, a condition characterized by signs of adrenergic excess, including: hypertension, tachycardia, hyperthermia, diaphoresis, minimally-reactive mydriasis, and agitation. The diagnosis of methamphetamine intoxication in patients with these findings is supported by a positive result on the amphetamine portion of a qualitative urine drug screen (\"tox screen\"). The differential diagnosis includes toxicologic and nontoxicologic etiologies.",
"   </p>",
"   <p>",
"    Toxicologic conditions mimicking methamphetamine intoxication include (",
"    <a class=\"graphic graphic_table graphicRef61832 \" href=\"UTD.htm?2/40/2700\">",
"     table 1",
"    </a>",
"    ): adrenergic substances (eg, cocaine, phencyclidine [PCP]),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , monoamine oxidase inhibitors, serotonin syndrome, and anticholinergic poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"     \"Theophylline poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prolonged duration of action of methamphetamine (approximately 20 hours) helps differentiate it from cocaine (duration of action 30 minutes) and PCP (duration of action less than 8 hours). The clinically distinct features of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    intoxication (tachycardia, unremitting vomiting, and widened pulse pressure) are confirmed by measurement of the serum theophylline concentration.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    intoxication produces tinnitus and hyperpnea even in resting patients, as well as metabolic acidosis, hyperthermia, and elevated serum aspirin concentrations.",
"   </p>",
"   <p>",
"    Monoamine oxidase inhibitor poisoning has a clinical appearance nearly identical to serotonin syndrome, and both share clinical features with methamphetamine toxicity. While the clinical manifestations of serotonin syndrome include agitation, tachycardia, and diaphoresis, they also include lower extremity tremor and clonus, which distinguish the condition from methamphetamine intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with anticholinergic poisoning have anhidrosis, whereas methamphetamine intoxicated individuals are profusely diaphoretic. Furthermore, patients with the anticholinergic toxidrome feebly pick at objects and have a peculiar mumbling speech; methamphetamine produces wildly agitated delirium that often requires a combination of physical and chemical restraint.",
"   </p>",
"   <p>",
"    Leading nontoxicologic mimics of methamphetamine intoxication include heat stroke, thyrotoxicosis, and pheochromocytoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis of heat stroke should have corroborating history, such as a hot environment, prolonged exercise or exertion, or decreased ability to regulate temperature. Associated medication (such as diuretics, antipsychotics, and some cardiovascular medications) or conditions (such as advanced age, intoxication, debility, and autonomic dysfunction) predispose certain patients to heat stroke. The degree of agitation in heat stroke is significantly less than that seen in methamphetamine intoxication.",
"   </p>",
"   <p>",
"    While thyrotoxicosis may have several features consistent with methamphetamine intoxication, presence of goiter, thyroid artery bruit, exophthalmos, and pretibial edema are seen only in thyrotoxicosis. The associated agitation is also unlikely to be as severe as with methamphetamine. Pheochromocytoma usually produces intermittent hypertension, diaphoresis, vomiting, and diarrhea; duration of episodes is variable and may be associated with inciting stimulus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       General testing",
"      </strong>",
"      &mdash; Routine laboratory evaluation of the poisoned patient should include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system impairment by drugs that prolong the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Specific testing",
"      </strong>",
"      &mdash; Reliance upon qualitative toxicologic screens can be disastrous if care is delayed while awaiting test results. Although urine drug tests may support the diagnosis of acute methamphetamine intoxication, the results of such a \"tox screen\" have little clinical utility.",
"      <br/>",
"      <br/>",
"      The amphetamine portion of the tox screen is susceptible to both false positive and false negative results and must be interpreted in clinical context [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/36\">",
"       36",
"      </a>",
"      ]. Drugs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/56/36741?source=see_link\">",
"       benzphetamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , may give positive results [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/37,38\">",
"       37,38",
"      </a>",
"      ], as may",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"       selegiline",
"      </a>",
"      following its metabolism to l-methamphetamine. Conversely, urine drug assays, which are dependent upon renal clearance, may fail to detect methamphetamine if insufficient time has elapsed for drug to be excreted in the urine [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/39\">",
"       39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Because of these concerns, clinicians should not withhold immediate sedation for an acutely intoxicated individual while awaiting final test results.",
"      <br/>",
"      <br/>",
"      Because hypovolemia, metabolic acidosis, hyperthermia, and rhabdomyolysis occur in a large number of methamphetamine users, we recommend the following tests also be obtained if methamphetamine intoxication is suspected:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Basic serum electrolytes (ie, sodium, chloride, potassium, bicarbonate)",
"     </li>",
"     <li>",
"      Serum lactate",
"     </li>",
"     <li>",
"      Creatinine phosphokinase (CPK)",
"     </li>",
"     <li>",
"      Aminotransferases (ie, ALT, AST)",
"     </li>",
"     <li>",
"      Clotting times (ie, prothrombin time, activated partial thromboplastin time)",
"     </li>",
"     <li>",
"      Renal function studies (ie, creatinine, BUN)",
"      <br/>",
"      <br/>",
"      Rhabdomyolysis can cause acute renal failure and hyperkalemia in methamphetamine abusers [",
"      <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/16,40\">",
"       16,40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      An arterial blood gas can confirm the presence and severity of metabolic acidosis (usually lactic acidosis) in a patient with a low serum bicarbonate and an elevated anion gap. Pelvic ultrasonography may be helpful in diagnosing placental abruption, but its sensitivity is limited and emergent obstetrical consultation is needed if this diagnosis is entertained.",
"      <br/>",
"      <br/>",
"      Additional studies, including echocardiography, chest and abdominal CT, and chest radiography, are obtained as needed to investigate other potential complications of methamphetamine abuse, such as cardiomyopathy, aortic dissection and rupture, pneumothorax, and stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General approach and warning about agitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should consider the diagnosis of methamphetamine intoxication in any diaphoretic patient with hypertension, tachycardia, severe agitation, and psychosis. In addition, patients with acute methamphetamine intoxication may, without provocation, abruptly develop severe agitation and manifest extreme violence. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef73681 \" href=\"UTD.htm?20/26/20909\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Control of agitation and hyperthermia comprise the core of the acute management of methamphetamine intoxication. Some patients also require pharmacologic therapy for control of hypertension. Patients who appear hypovolemic may need fluid resuscitation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Hypertension'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The intensity of therapy depends upon the severity of illness, but cases of abrupt decompensation among conservatively treated patients highlight the need for immediate, aggressive intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/16,41\">",
"     16,41",
"    </a>",
"    ]. Interventions frequently must be initiated prior to confirmatory laboratory data or, in violent patients, even before vital signs are obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acutely intoxicated patients may become extremely agitated and pose a danger to themselves, other patients, and medical staff. Control of violent behavior is of critical importance. We treat severely intoxicated patients immediately with intravenous (IV) benzodiazepines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    4 mg IV or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    5 to 10 mg IV). These doses can be repeated every eight to ten minutes based upon patient response; high cumulative doses may be needed. In animal models, benzodiazepines blunt the hyperadrenergic effects of methamphetamine, an outcome associated with increased survival.",
"   </p>",
"   <p>",
"    Second generation antipsychotic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    10 mg IM), butyrophenones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    2.5 to 5 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    10 mg given IM or IV), or combinations of these agents can be used as adjunctive therapy when benzodiazepines do not adequately control symptoms. Although some studies support the use of butyrophenones [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/42-44\">",
"     42-44",
"    </a>",
"    ], these agents may interfere with heat dissipation, lower the seizure threshold, and prolong the QTc interval [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although intravenous administration of sedatives and antipsychotics is strongly preferred in severely intoxicated patients, intramuscular (IM) injection may be used if IV access is unavailable. IM injection may provide sufficient sedation to allow definitive care, including placement of intravenous catheters.",
"   </p>",
"   <p>",
"    A less aggressive regimen can be used in patients who are mildly or moderately intoxicated. This includes a quiet environment with minimal sedation in mild intoxications plus, in moderate intoxication, a benzodiazepine.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    1 to 2 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    2 to 5 mg may be adequate to sedate these patients, and should be repeated as needed.",
"   </p>",
"   <p>",
"    Physical restraints are undesirable. Patients who struggle against physical restraints undergo isometric muscle contractions that can be associated with lactic acidosis, hyperthermia, sudden cardiac collapse, and death. When necessary, physical restraints should be replaced by chemical sedation as rapidly as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely intoxicated hyperthermic patients may require paralysis and endotracheal intubation. Additional indications for endotracheal intubation include refractory agitation; skeletal, cervical, or facial muscle rigidity; and worsening, severe metabolic acidosis. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Hyperthermia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    because of the risk of rhabdomyolysis from severe methamphetamine intoxication, which can cause an acute rise in serum potassium that can impair cardiac conduction. Instead, nondepolarizing agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    , are used to perform rapid sequence intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with increased respiratory rate and effort, some toxicologists give 50 to 150 mEq (one to three 50 mEq [50 mL] vials or prefilled syringes) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    prior to intubation to treat a presumptive underlying metabolic acidosis. However, the efficacy of bicarbonate therapy in lactic acidosis is unproven in the absence of severe acidemia and has potential harm. Paralyzed patients at risk for seizures should receive continuous bedside electroencephalography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hypertension, particularly if refractory to aggressive treatment with sedatives, may require treatment with intravenous antihypertensive drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    . The use of beta blockers, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    , to manage hypertension should be avoided in any hyperadrenergic state, since they can lead to unopposed alpha-adrenergic vasoconstriction, and paradoxical worsening of the hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=see_link\">",
"     \"Drug treatment of hypertensive emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of hyperthermia (temperature &ge;41.1&ordm;C) involves eliminating excessive muscle activity. While benzodiazepines alone offer benefit to moderately ill patients, severely intoxicated hyperthermic patients may require paralysis with nondepolarizing agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    , followed by tracheal intubation and mechanical ventilation. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Airway management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Aggressive sedation, neuromuscular paralysis, and fluid resuscitation are used to control methamphetamine-induced hyperthermia; these measures can be supplemented with external cooling blankets or evaporative cooling techniques. Paralyzed patients at risk for seizures should receive continuous bedside electroencephalography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antipyretics have",
"    <strong>",
"     NO ROLE",
"    </strong>",
"    in the management of acute methamphetamine intoxication. Increased body temperature in this setting arises from muscular activity, not an alteration in the hypothalamic temperature set point.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fluid resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of fluid resuscitation in patients with severe methamphetamine intoxication is not defined. One problem is the limited utility of some traditional markers for hypovolemia in this setting. Tachycardia is almost universal and many patients are hypertensive. Thus, both heart rate and blood pressure may prove unhelpful when assessing volume status. In addition, there is potential for harm from aggressive fluid resuscitation in patients who are acutely hypertensive and may have myocardial dysfunction, possibly leading to pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. If a patient with methamphetamine toxicity is thought to be hypovolemic, resuscitation using isotonic saline is appropriate. Patients receiving fluid resuscitation should be monitored for fluid overload.",
"   </p>",
"   <p>",
"    If severe lactic acidosis (pH &lt;7.10) or rhabdomyolysis is present, we suggest intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    to raise the arterial pH above 7.15 in lactic acidosis and to alkalinize the urine to protect against the development of acute renal failure in rhabdomyolysis. The bicarbonate solution should be isotonic (eg, three 50 mEq [50 mL] vials or prefilled syringes of sodium bicarbonate in 5 percent dextrose with water) and administered at a rate of 200",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"    These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link&amp;anchor=H25398978#H25398978\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sudden cardiac arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite appropriate and expeditious management, some patients with severe methamphetamine intoxication will sustain sudden cardiovascular collapse. No predisposing factors rigorously predict collapse, but the clinician should anticipate clinical deterioration and cardiac arrest in any wildly agitated patient, particularly those requiring physical restraints to maintain patient safety [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients placed in physical restraints can suffer sudden cardiac arrest due to a combination of dehydration, depletion of adrenergic neurotransmitters, and metabolic acidosis. Contributing factors to metabolic acidosis may include excessive muscular activity and increased ATP hydrolysis from methamphetamine-induced increases in metabolism. The multifactorial nature of cardiovascular collapse makes successful resuscitation notoriously difficult, even when arrest is witnessed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition to airway control with endotracheal intubation, therapy is directed toward:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Administration of vasoactive amines to overcome neurotransmitter depletion",
"     </li>",
"     <li>",
"      Correction of metabolic acidosis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"     </li>",
"     <li>",
"      Fluid resuscitation with large volumes of normal saline",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A direct-acting vasopressor, such as norepinephrine, is preferred for management of shock associated with methamphetamine intoxication. Continuous norepinephrine administration should be titrated to a systolic blood pressure greater that 90 mmHg and a urine output greater than 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour. The use of direct-acting vasopressor amines, such as norepinephrine and epinephrine, is postulated to be more effective at reestablishing effective vascular tone than indirect vasopressors, such as dopamine, which require neuronal uptake and conversion to norepinephrine.",
"   </p>",
"   <p>",
"    Treatment of metabolic acidosis consists of fluid resuscitation, as described above, and administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , 50 to 150 mEq (one to three 50 mEq [50 mL] vials or prefilled syringes) administered intravenously. Intravenous fluids should be administered until circulation is restored. Specific guidelines for fluid administration in methamphetamine-associated cardiovascular collapse are lacking, but a useful starting point is a bolus of 2 liters of normal saline (or 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    in a child) administered over 30 minutes, followed by repeat boluses as needed.",
"   </p>",
"   <p>",
"    Hyperkalemic cardiac arrest may occur in acute methamphetamine intoxication; patients with a suggestive electrocardiogram may benefit from standard treatment with calcium and insulin with dextrose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    is rarely indicated due to the route of administration (eg, intranasal, inhalation, injection). If methamphetamine has been ingested, the greatest benefit of activated charcoal occurs if administered within one to two hours of ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/50\">",
"     50",
"    </a>",
"    ]. Activated charcoal should not be given to a patient with a declining mental status, severe agitation requiring sedation, or at risk of seizure. If given, the standard dose is 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (maximum of 50 g).",
"   </p>",
"   <p>",
"    In the case of a single large recent ingestion, body packing or stuffing, or a slow-release mechanism (ie, \"parachuting,\" in which the drug is folded into plastic or paper before swallowing allowing for gradual absorption), GI decontamination with whole bowel irrigation using agents, such as polyethylene glycol, may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/7,51\">",
"     7,51",
"    </a>",
"    ]. We suggest such treatment be done in consultation with a medical toxicologist or poison control center since individuals who have gastrointestinal exposure to methamphetamine (eg, body stuffers) and abdominal pain may deserve immediate laparotomy to prevent bowel ischemia from local vasoconstriction. Gastric lavage is unlikely to be of benefit, and is discouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Enhanced elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine acidification, formerly used to promote the elimination of methamphetamine, is no longer recommended. The administration of acidic intravenous fluids may exacerbate life-threatening metabolic acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5267653\">",
"    <span class=\"h2\">",
"     Seizure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures caused by acute methamphetamine intoxication are usually brief and self-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Prolonged seizures are treated initially with benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ) and should prompt a search for causes other than isolated methamphetamine intoxication (eg, hypoglycemia, intracranial hemorrhage).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pediatric exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric exposure to methamphetamine may be intentional (typically seen in adolescents), or unintentional (in neonates, infants, or children). Presentation and management of methamphetamine-related illness in adolescents is largely similar to that of adults, but with an increased need for attention to social ramifications.",
"   </p>",
"   <p>",
"    In children and infants, inadvertent exposure to methamphetamine is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/52\">",
"     52",
"    </a>",
"    ]. Although sympathomimetic and neuropsychiatric manifestations of methamphetamine exposure should be similar in a pediatric patient, inadvertent exposure may be difficult to diagnose. Caregivers may not be forthcoming about access to this illicit substance, and the most frequent signs and symptoms noted in pediatric patients exposed to methamphetamine are nonspecific.",
"   </p>",
"   <p>",
"    Agitation, tachycardia, and crying are the most common symptoms of exposure in young children, followed by vomiting with or without abdominal pain, hyperthermia, ataxia, mydriasis, seizures, and roving eye movements.",
"   </p>",
"   <p>",
"    Evaluation often includes an extensive workup to exclude other neurologic or abdominal pathologies. Methamphetamine poisoning has even been mistaken for scorpion envenomation (Centruroides sculpturatus) with administration of antivenom [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/52\">",
"     52",
"    </a>",
"    ]. Additionally, caustic ingestion or injury in the pediatric patient should prompt consideration for methamphetamine exposure; such presentations may be more common among children living in methamphetamine-production sites (or meth labs) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/53\">",
"     53",
"    </a>",
"    ]. Once methamphetamine exposure is suspected, we recommend that routine laboratory work and an electrocardiogram be performed to evaluate for possible rhabdomyolysis and methamphetamine-induced ischemia.",
"   </p>",
"   <p>",
"    Symptoms may persist up to 24 hours, and ongoing management may require frequent vital signs, telemetry monitoring, sedation, aggressive cooling measures, control of hypertension with rapid-acting agents, and intravenous fluid hydration to maintain urine output of one to two",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    to prevent myoglobinuric renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H18#H18\">",
"     \"Heat stroke in children\", section on 'Rapid cooling'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link\">",
"     \"Management of hypertensive emergencies and urgencies in children\"",
"    </a>",
"    .) Hospitalization should continue until appropriate social and child protection services are enlisted.",
"   </p>",
"   <p>",
"    Asymptomatic children taken from clandestine production sites may also have been exposed to methamphetamine and other chemicals (eg, ephedrine) used to synthesize methamphetamine, according to a retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/54\">",
"     54",
"    </a>",
"    ]. In this review, 48 of the 104 infants and children included tested positive for methamphetamine; 85 percent of children younger than nine years had positive toxicology screens.",
"   </p>",
"   <p>",
"    Special attention should be given to children living at methamphetamine-manufacturing sites (ie, meth labs), whose numbers have increased substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/22\">",
"     22",
"    </a>",
"    ]. They are often discovered after an in-home fire or explosion. Any child brought from such an environment requires initial decontamination to prevent exposing healthcare workers to toxic chemicals. These children are particularly vulnerable to child abuse, neglect, serious injury, exposure to toxic chemicals, and malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/55\">",
"     55",
"    </a>",
"    ]. The hypersexuality and drug-seeking behaviors of adult methamphetamine users may lead to sexual abuse of such children, or they may be prostituted for money or drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pregnancy and lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine demonstrates teratogenic and embryocidal effects in mammals. Prenatal exposure to methamphetamine has been linked to growth restriction, low birth weight, and withdrawal symptoms in the perinatal period. There is an increased risk of perinatal complication, such as placental hemorrhage, in methamphetamine-exposed mothers. Amphetamines, including methamphetamine, are excreted into breast milk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of illicit drug use in pregnant women\", section on 'Amphetamines including methamphetamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PITFALLS IN MANAGEMENT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Failure to respect agitation",
"      </strong>",
"      &ndash; Uncontrolled agitation results in hyperthermia, acidosis, rhabdomyolysis, and sudden cardiovascular collapse. Control of agitation and chemical sedation is a clinical priority.",
"     </li>",
"     <li>",
"      <strong>",
"       Failure to respect hyperthermia",
"      </strong>",
"      &ndash; Hyperthermia is strongly associated with mortality and morbidity if not rapidly corrected.",
"     </li>",
"     <li>",
"      <strong>",
"       Failure to recognize rhabdomyolysis",
"      </strong>",
"      &ndash; A frequent complication of methamphetamine intoxication, rhabdomyolysis contributes to renal failure and hyperkalemia.",
"     </li>",
"     <li>",
"      <strong>",
"       Failure to consider associated illness",
"      </strong>",
"      &ndash; Methamphetamine-intoxicated patients are frequently the victims of traumatic injury. In addition, methamphetamine users may suffer from a range of complications, including: intracranial hemorrhage, myocardial infarction, aortic dissection, pulmonary edema or hemorrhage, endocarditis, injection site abscess, and placental abruption.",
"     </li>",
"     <li>",
"      <strong>",
"       Failure to note risk of contamination",
"      </strong>",
"      &ndash; Methamphetamine synthetic labs are often contaminated with toxic chemicals. Patients who work in or have contact with such labs may need decontamination to prevent poisoning patients and staff.",
"     </li>",
"     <li>",
"      <strong>",
"       Failure to appreciate the risk of violence",
"      </strong>",
"      &ndash; Methamphetamine-intoxicated patients can demonstrate a striking degree of violence. The use of physical and chemical restraints, personnel, and police is often required to ensure the safety of care providers and other patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ACUTE WITHDRAWAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent methamphetamine abuse leads to derangements in neurochemistry, the consequences of which include compulsive and uncontrolled drug intake and addiction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/57\">",
"     57",
"    </a>",
"    ]. Particularly after heavy or prolonged use, abrupt discontinuation of methamphetamine can cause a withdrawal syndrome. Symptoms may develop within hours, typically peak within one to two days, and most often decrease within two weeks. During the acute withdrawal phase (\"the crash\"), signs and symptoms may include: dysphoria, anhedonia, fatigue, increased sleep, vivid dreams, insomnia, agitation, anxiety, drug craving, and increased appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?0/29/474/abstract/58\">",
"     58",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    A subacute withdrawal phase may persist for up to three weeks with insomnia, hypersomnia, appetite changes, depression, and possibly suicidal thoughts. Studies have yet to identify a proven medication regimen for the treatment of methamphetamine withdrawal, but treatments have included benzodiazepines, antidepressants, antipsychotics, and behavioral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12763789\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef73681 \" href=\"UTD.htm?20/26/20909\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Methamphetamine is a sympathomimetic with a variety of stimulant, anorexiant, euphoric, and hallucinogenic effects. Methamphetamine is readily absorbed following administration via oral, pulmonary, nasal, intramuscular, intravenous, rectal, and vaginal routes. The pharmacology and kinetics of methamphetamine are discussed in the text. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and cellular toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacokinetics and metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should consider the diagnosis of methamphetamine intoxication in any diaphoretic patient with hypertension, tachycardia, severe agitation, and psychosis. Patients with methamphetamine intoxication range from the virtually asymptomatic to those in sympathomimetic crisis with imminent cardiovascular collapse. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methamphetamine can cause a host of respiratory, cardiac, vascular, otolaryngologic, neurologic, integumentary, psychiatric, infectious, traumatic, and dental maladies. Agitation, tachycardia, hypertension, and psychosis are among the most frequent findings. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In severe intoxication, prognostic factors for mortality include: coma, shock, body temperature &gt;39&ordm;C, acute renal failure, metabolic acidosis, and hyperkalemia (serum potassium 5.6 to 8.5",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      The clinician should anticipate clinical deterioration and cardiac arrest in any wildly agitated patient, particularly those requiring physical restraints to maintain patient safety. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of overdose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Sudden cardiac arrest'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes a number of poisonings and medical conditions with characteristics of the sympathomimetic toxidrome, a condition characterized by signs of adrenergic excess. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reliance upon qualitative toxicologic screens can be disastrous if care is delayed while awaiting test results. While urine drug tests may support the diagnosis of acute methamphetamine intoxication, the results of such a \"tox screen\" have little clinical utility. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute methamphetamine intoxication may, without provocation, abruptly develop severe agitation and manifest extreme violence, placing themselves, their caretakers, and other patients at risk of major injury. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'General approach and warning about agitation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Sedation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef73681 \" href=\"UTD.htm?20/26/20909\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intensity of therapy depends upon the severity of illness, but patients can decompensate abruptly, highlighting the need for immediate, aggressive intervention, even in the absence of confirmatory laboratory data. Control of agitation and hyperthermia comprise the core of management. Common management pitfalls are described above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Pitfalls in management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Control of violent behavior is of critical importance. We suggest severely intoxicated patients be treated immediately with parenteral benzodiazepines (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Reasonable initial doses include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      4 mg IV or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 to 10 mg IV. These doses can be repeated every eight to ten minutes based on patient response; very large doses may be needed. IV administration is strongly preferred; intramuscular (IM) injection may be used initially when IV access is unavailable. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sedation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atypical antipsychotic agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      10 mg), butyrophenones (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"       droperidol",
"      </a>",
"      2.5 to 5 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      10 mg given IM or IV), or combinations of these agents can be used as adjunctive therapy when high doses of benzodiazepines do not adequately control symptoms. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sedation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe hypertension, particularly if refractory to aggressive treatment with sedatives, may require treatment with vasodilators (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ) or alpha-adrenergic antagonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"       phentolamine",
"      </a>",
"      ). The use of beta-adrenergic antagonists (beta-blockers), including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      , should be avoided. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Control of hyperthermia (T &ge;41.1&ordm;C) involves eliminating excessive muscle activity. While benzodiazepines alone offer benefit to moderately ill patients, severely intoxicated hyperthermic patients may require paralysis with nondepolarizing agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      , followed by tracheal intubation and mechanical ventilation.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       Succinylcholine",
"      </a>",
"      is",
"      <strong>",
"       contraindicated",
"      </strong>",
"      because of the risk of rhabdomyolysis and hyperkalemic arrhythmias. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hyperthermia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children and infants, inadvertent exposure to methamphetamine is increasing and may be difficult to diagnose. Agitation, tachycardia, and crying are the most common symptoms of exposure in young children, followed by vomiting with or without abdominal pain, hyperthermia, ataxia, mydriasis, seizures, and roving eye movements. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Pediatric considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     2010 World Drug Report, Volume 1: Analysis.  United Nations Office on Drugs and Crime. file://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf (Accessed on January 13, 2011).",
"    </li>",
"    <li>",
"     Substance Abuse and Mental Health Services Administration. (2010). Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. file://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf (Accessed on January 13, 2011).",
"    </li>",
"    <li>",
"     Drug Policy Information Clearinghouse Fact Sheet: Methamphetamine. Office of National Drug Control Policy, Rockville, MD, November 2003 www.whitehousedrugpolicy.gov (Accessed on June 15, 2007).",
"    </li>",
"    <li>",
"     Results from the 2004 National Survey on Drug Use and Health: National Findings. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies,NSDUH Series H-28, DHHS Publication No. SMA 05-4062, Rockville, MD. www.samhsa.gov (Accessed on June 15, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/5\">",
"      Hendrickson RG, Cloutier R, McConnell KJ. Methamphetamine-related emergency department utilization and cost. Acad Emerg Med 2008; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     United States Drug Enforcement Administration. Methamphetamine. www.usdoj.gov/dea/concern/meth_factsheet.html (Accessed on June 15, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/7\">",
"      Hendrickson RG, Horowitz BZ, Norton RL, Notenboom H. \"Parachuting\" meth: a novel delivery method for methamphetamine and delayed-onset toxicity from \"body stuffing\". Clin Toxicol (Phila) 2006; 44:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/8\">",
"      Cantrell FL, Breckenridge HM, Jost P. Transrectal methamphetamine use: a novel route of exposure. Ann Intern Med 2006; 145:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/9\">",
"      Kashani J, Ruha AM. Methamphetamine toxicity secondary to intravaginal body stuffing. J Toxicol Clin Toxicol 2004; 42:987.",
"     </a>",
"    </li>",
"    <li>",
"     Chiang WK. Amphetamines. In: Goldfrank's Toxicologic Emergencies, 8th, Goldfrank LR (Ed), McGraw-Hill, New York 2006. p.1118.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/11\">",
"      Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13:141.",
"     </a>",
"    </li>",
"    <li>",
"     Desoxyn Drug Insert/Information.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/13\">",
"      West PL, McKeown NJ, Hendrickson RG. Methamphetamine body stuffers: an observational case series. Ann Emerg Med 2010; 55:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/14\">",
"      Gray SD, Fatovich DM, McCoubrie DL, Daly FF. Amphetamine-related presentations to an inner-city tertiary emergency department: a prospective evaluation. Med J Aust 2007; 186:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/15\">",
"      Derlet RW, Rice P, Horowitz BZ, Lord RV. Amphetamine toxicity: experience with 127 cases. J Emerg Med 1989; 7:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/16\">",
"      Chan P, Chen JH, Lee MH, Deng JF. Fatal and nonfatal methamphetamine intoxication in the intensive care unit. J Toxicol Clin Toxicol 1994; 32:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/17\">",
"      Richards JR, Bretz SW, Johnson EB, et al. Methamphetamine abuse and emergency department utilization. West J Med 1999; 170:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/18\">",
"      Swanson SM, Sise CB, Sise MJ, et al. The scourge of methamphetamine: impact on a level I trauma center. J Trauma 2007; 63:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/19\">",
"      Tominaga GT, Garcia G, Dzierba A, Wong J. Toll of methamphetamine on the trauma system. Arch Surg 2004; 139:844.",
"     </a>",
"    </li>",
"    <li>",
"     Methamphetamine dosage by Erowid. www.erowid.org/chemicals/meth/meth_dose.shtml (Accessed on March 05, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/21\">",
"      Turnipseed SD, Richards JR, Kirk JD, et al. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med 2003; 24:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/22\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010; 48:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/23\">",
"      Blostein PA, Plaisier BR, Maltz SB, et al. Methamphetamine production is hazardous to your health. J Trauma 2009; 66:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/24\">",
"      Santos AP, Wilson AK, Hornung CA, et al. Methamphetamine laboratory explosions: a new and emerging burn injury. J Burn Care Rehabil 2005; 26:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/25\">",
"      Nestor TA, Tamamoto WI, Kam TH, Schultz T. Crystal methamphetamine-induced acute pulmonary edema: a case report. Hawaii Med J 1989; 48:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/26\">",
"      Schaiberger PH, Kennedy TC, Miller FC, et al. Pulmonary hypertension associated with long-term inhalation of \"crank\" methamphetamine. Chest 1993; 104:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/27\">",
"      Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006; 130:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/28\">",
"      Gotway MB, Marder SR, Hanks DK, et al. Thoracic complications of illicit drug use: an organ system approach. Radiographics 2002; 22 Spec No:S119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/29\">",
"      Johnson TD, Berenson MM. Methamphetamine-induced ischemic colitis. J Clin Gastroenterol 1991; 13:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/30\">",
"      Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. J Pediatr 1987; 111:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/31\">",
"      Sperling LS, Horowitz JL. Methamphetamine-induced choreoathetosis and rhabdomyolysis. Ann Intern Med 1994; 121:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/32\">",
"      Alldredge BK, Lowenstein DH, Simon RP. Seizures associated with recreational drug abuse. Neurology 1989; 39:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/33\">",
"      Olson KR, Kearney TE, Dyer JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1993; 11:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/34\">",
"      Zweben JE, Cohen JB, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict 2004; 13:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/35\">",
"      Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/36\">",
"      elSohly MA, Jones AB. Drug testing in the workplace: could a positive test for one of the mandated drugs be for reasons other than illicit use of the drug? J Anal Toxicol 1995; 19:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/37\">",
"      Nixon AL, Long WH, Puopolo PR, Flood JG. Bupropion metabolites produce false-positive urine amphetamine results. Clin Chem 1995; 41:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/38\">",
"      Cody JT, Valtier S. Detection of amphetamine and methamphetamine following administration of benzphetamine. J Anal Toxicol 1998; 22:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/39\">",
"      Valentine JL, Kearns GL, Sparks C, et al. GC-MS determination of amphetamine and methamphetamine in human urine for 12 hours following oral administration of dextro-methamphetamine: lack of evidence supporting the established forensic guidelines for methamphetamine confirmation. J Anal Toxicol 1995; 19:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/40\">",
"      Lan KC, Lin YF, Yu FC, et al. Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc 1998; 97:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/41\">",
"      Espelin DE, Done AK. Amphetamine poisoning. Effectiveness of chlorpromazine. N Engl J Med 1968; 278:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/42\">",
"      Richards JR, Derlet RW, Duncan DR. Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med 1997; 4:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/43\">",
"      Ruha AM, Yarema MC. Pharmacologic treatment of acute pediatric methamphetamine toxicity. Pediatr Emerg Care 2006; 22:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/44\">",
"      Martel M, Sterzinger A, Miner J, et al. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med 2005; 12:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/45\">",
"      Delbridge TR, Yealy DM. Wide complex tachycardia. Emerg Med Clin North Am 1995; 13:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/46\">",
"      Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med 1995; 333:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/47\">",
"      Chen JP. Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm. J Invasive Cardiol 2007; 19:E89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/48\">",
"      Wijetunga M, Bhan R, Lindsay J, Karch S. Acute coronary syndrome and crystal methamphetamine use: a case series. Hawaii Med J 2004; 63:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/49\">",
"      Hick JL, Smith SW, Lynch MT. Metabolic acidosis in restraint-associated cardiac arrest: a case series. Acad Emerg Med 1999; 6:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/50\">",
"      Chyka PA, Seger D, Krenzelok EP, et al. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila) 2005; 43:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/51\">",
"      Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004; 42:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/52\">",
"      Kolecki P. Inadvertent methamphetamine poisoning in pediatric patients. Pediatr Emerg Care 1998; 14:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/53\">",
"      Farst K, Duncan JM, Moss M, et al. Methamphetamine exposure presenting as caustic ingestions in children. Ann Emerg Med 2007; 49:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/54\">",
"      Grant P, Bell K, Stewart D, et al. Evidence of methamphetamine exposure in children removed from clandestine methamphetamine laboratories. Pediatr Emerg Care 2010; 26:10.",
"     </a>",
"    </li>",
"    <li>",
"     Information Bulletin: Children at Risk, National Drug Intelligence Center, Publication no. 2002-L0424-001. www.usdoj.gov/ndic/pubs1/1466/index.htm (Accessed on August 22, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/56\">",
"      Bellemare S. Dangers for children in the care of drug users. CMAJ 2008; 179:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/57\">",
"      Kitanaka J, Kitanaka N, Takemura M. Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: a review. Neurochem Res 2008; 33:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/29/474/abstract/58\">",
"      Mancino MJ, Gentry BW, Feldman Z, et al. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse 2011; 37:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 311 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_474=[""].join("\n");
var outline_f0_29_474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOKINETICS AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General approach and warning about agitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fluid resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Enhanced elimination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5267653\">",
"      Seizure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pediatric exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PITFALLS IN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ACUTE WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12763789\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/311\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/311|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/4/42060\" title=\"figure 1\">",
"      Phenethylamine structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/32/8717\" title=\"figure 2\">",
"      Amphetamine structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/46/29420\" title=\"figure 3\">",
"      Methamphetamine structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/311|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/26/36260\" title=\"picture 1\">",
"      Meth mouth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/21/6482\" title=\"picture 2\">",
"      Skin popping in substance abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/44/5829\" title=\"picture 3\">",
"      Skin excoriations in chronic methamphetamine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/311|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/40/2700\" title=\"table 1\">",
"      Differential diagnosis for methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/26/20909\" title=\"table 2\">",
"      Methamphetamine intoxication in adults - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=related_link\">",
"      Heat stroke in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=related_link\">",
"      Management of hypertensive emergencies and urgencies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=related_link\">",
"      Pulmonary complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=related_link\">",
"      Theophylline poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_29_475="Chromosomal locat TCR gene";
var content_f0_29_475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chromosomal locations of T-Cell receptor genes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Locus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &alpha;, &delta;",
"       </td>",
"       <td>",
"        14q11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &beta;",
"       </td>",
"       <td>",
"        7q35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gamma;",
"       </td>",
"       <td>",
"        7p15",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_475=[""].join("\n");
var outline_f0_29_475=null;
var title_f0_29_476="Dx and initial assessment";
var content_f0_29_476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sample questions* for the diagnosis and initial assessment of asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A \"yes\" answer to any question suggests that an asthma diagnosis is likely.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        In the past 12 months...",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Have you had a sudden severe episode or recurrent episodes of coughing, wheezing (high-pitched whistling sounds when breathing out), chest tightness, or shortness of breath?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Have you had colds that \"go to the chest\" or take more than 10 days to get over?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Have you had coughing, wheezing, or shortness of breath during a particular season or time of the year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Have you had coughing, wheezing, or shortness of breath in certain places or when exposed to certain things (eg, animals, tobacco smoke, perfumes)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Have you used any medications that help you breathe better? How often?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Are your symptoms relieved when the medications are used?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        In the past 4 weeks, have you had coughing, wheezing, or shortness of breath...",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        At night that has awakened you?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upon awakening?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        After running, moderate exercise, or other physical activity?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These questions are examples and do not represent a standardized assessment or diagnostic instrument. The validity and reliability of these questions have not been assessed.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_476=[""].join("\n");
var outline_f0_29_476=null;
var title_f0_29_477="Risk factors for death in adult destination therapy patients";
var content_f0_29_477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F85809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F85809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for death in destination therapy patients (Adult Primary Implants from June 2006 to June 2010) from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"30%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"17%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Early hazard",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Constant hazard",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        HR",
"       </td>",
"       <td class=\"subtitle2\">",
"        p-value",
"       </td>",
"       <td class=\"subtitle2\">",
"        HR",
"       </td>",
"       <td class=\"subtitle2\">",
"        p-value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age (older)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1.78*",
"       </td>",
"       <td>",
"        &lt;0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Critical cardiogenic shock",
"       </td>",
"       <td>",
"        3.52",
"       </td>",
"       <td>",
"        0.0078",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1.98",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary hypertension",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3.56",
"       </td>",
"       <td>",
"        0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BUN (higher)",
"       </td>",
"       <td>",
"        1.27",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium (lower)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2.14",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concomitant surgery",
"       </td>",
"       <td>",
"        3.02",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bi-VAD",
"       </td>",
"       <td>",
"        8.42",
"       </td>",
"       <td>",
"        0.0002",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulsatile flow LVAD",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2.75",
"       </td>",
"       <td>",
"        0.002",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Risk factors for death in destination therapy patients (Adult Primary Implants from June 2006 to June 2010) from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS).",
"    <div class=\"footnotes\">",
"     BUN: blood urea nitrogen; INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; LVAD: left ventricular assist device; HR: hazard ratio.",
"     <br/>",
"     * The hazard ratio denotes the increased risk from age 60 to 70 years.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The hazard ratio denotes the increased risk of a 10-unit increase in BUN.",
"     <br/>",
"     &Delta; The hazard ratio denotes the increased risk of a 10-unit decrease in sodium.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant 2011; 30:115. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_477=[""].join("\n");
var outline_f0_29_477=null;
var title_f0_29_478="Immune globulins for intravenous administration";
var content_f0_29_478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immune globulins for intravenous administration (IVIG or IGIV)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Trade name (US)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer (processed by)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Available form",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration, percent (grams IgG per 100 mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sugar",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sodium",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other*",
"       </td>",
"       <td class=\"subtitle1\">",
"        mOsms*",
"       </td>",
"       <td class=\"subtitle1\">",
"        IgA content",
"       </td>",
"       <td class=\"subtitle1\">",
"        Viral reduction steps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bivigam",
"       </td>",
"       <td>",
"        Biotest Pharmaceuticals",
"       </td>",
"       <td>",
"        Liquid",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Sodium chloride 0.1 to 0.14 mol/L",
"       </td>",
"       <td>",
"        <p>",
"         Glycine 0.2 to 0.29 mol/L",
"        </p>",
"        <p>",
"         Polysorbate 80 1.5 to 2.5 mg/mL",
"        </p>",
"       </td>",
"       <td>",
"        &lt;510 mOsm/kg",
"       </td>",
"       <td>",
"        &le;200 mcg/mL",
"       </td>",
"       <td>",
"        Precipitation/cold ethanol fractionation, S/D, nanofiltration, low pH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carimune NF",
"       </td>",
"       <td>",
"        CSL Behring",
"       </td>",
"       <td>",
"        Lyophilized",
"       </td>",
"       <td>",
"        3, 6, or 12",
"       </td>",
"       <td>",
"        1.67 gram sucrose per gram protein",
"       </td>",
"       <td>",
"        Sodium chloride&nbsp;&lt;20 mg per gram IgG",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        192-1074",
"        <sup>",
"         &bull;",
"        </sup>",
"        mOsm/kg",
"       </td>",
"       <td>",
"        1000-2000&nbsp;mcg/mL",
"       </td>",
"       <td>",
"        pH 4/pepsin treatment, nanofiltration, TSE removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flebogamma DIF",
"       </td>",
"       <td>",
"        Grifols",
"       </td>",
"       <td>",
"        Liquid",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50 mg/mL sorbitol",
"       </td>",
"       <td>",
"        Trace &lt;3.2 mmol/L",
"       </td>",
"       <td>",
"        PEG &le;6 mg/mL",
"       </td>",
"       <td>",
"        240-370 mOsm/kg",
"       </td>",
"       <td>",
"        &lt;6 mcg/mL",
"       </td>",
"       <td>",
"        Pasteurization, PEG precipitation, nanofiltration, Ph4 treatment,&nbsp;TSE removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gammagard Liquid",
"       </td>",
"       <td>",
"        Baxter",
"       </td>",
"       <td>",
"        Liquid",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Not detectable",
"       </td>",
"       <td>",
"        Glycine 0.25 mol/L",
"       </td>",
"       <td>",
"        240-300 mOsm/kg",
"       </td>",
"       <td>",
"        37 mcg/mL",
"       </td>",
"       <td>",
"        S/D, low pH treatment, nanofiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gammagard S/D",
"       </td>",
"       <td>",
"        Baxter",
"       </td>",
"       <td>",
"        Lyophilized",
"       </td>",
"       <td>",
"        5, 10",
"       </td>",
"       <td>",
"        20 mg/mL glucose",
"       </td>",
"       <td>",
"        85 mg/mL",
"       </td>",
"       <td>",
"        <p>",
"         Glycine 22.5 mg/mL",
"        </p>",
"        <p>",
"         PEG 2 mg/mL",
"        </p>",
"        <p>",
"         Polysorbate 80 100 mcg/mL",
"        </p>",
"       </td>",
"       <td>",
"        636 or 1250",
"        <sup>",
"         &bull;",
"        </sup>",
"        mOsm/L",
"       </td>",
"       <td>",
"        &le;1 mcg/mL",
"       </td>",
"       <td>",
"        S/D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gammaked",
"       </td>",
"       <td>",
"        Grifols",
"       </td>",
"       <td>",
"        Liquid",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Trace &lt;7 mEq/L",
"       </td>",
"       <td>",
"        Glycine 0.16 to 0.24 mol/L",
"       </td>",
"       <td>",
"        258 mOsm/kg",
"       </td>",
"       <td>",
"        46 mcg/mL (average)",
"       </td>",
"       <td>",
"        Caprylate chromotography purified, low pH incubation, TSE removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gammaplex",
"       </td>",
"       <td>",
"        Bio Products Laboratory",
"       </td>",
"       <td>",
"        Liquid&nbsp;",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5 percent D-sorbitol",
"       </td>",
"       <td>",
"        30-50 mmol/L",
"       </td>",
"       <td>",
"        <p>",
"         Glycine 6 mg/mL",
"        </p>",
"        <p>",
"         Polysorbate 80 ~5 mg/mL",
"        </p>",
"       </td>",
"       <td>",
"        420-500 mOsm/kg",
"       </td>",
"       <td>",
"        &lt;10 mcg/mL&nbsp;",
"       </td>",
"       <td>",
"        S/D, nanofiltration, low pH incubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gamunex-C",
"       </td>",
"       <td>",
"        Grifols",
"       </td>",
"       <td>",
"        Liquid",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Trace &lt;7 mEq/L",
"       </td>",
"       <td>",
"        Glycine 0.15 g/kg",
"       </td>",
"       <td>",
"        258 mOsm/kg",
"       </td>",
"       <td>",
"        46 mcg/mL",
"       </td>",
"       <td>",
"        Caprylate chromatography purified, low pH incubation, TSE removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Octagam",
"       </td>",
"       <td>",
"        Octopharma",
"       </td>",
"       <td>",
"        Liquid",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        100 mg/mL maltose",
"       </td>",
"       <td>",
"        &le;30 mmol/L",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        310-380 mOsm/kg",
"       </td>",
"       <td>",
"        &le;200 mcg/mL",
"       </td>",
"       <td>",
"        S/D, pH 4 treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Privigen",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        CSL Behring",
"       </td>",
"       <td>",
"        Liquid",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Trace &le;1 mmol/L",
"       </td>",
"       <td>",
"        L-proline",
"        <sup>",
"         &Delta;",
"        </sup>",
"        250 mmol/L",
"       </td>",
"       <td>",
"        220-440&nbsp;mOsm/kg",
"       </td>",
"       <td>",
"        &le;25 mcg/mL",
"       </td>",
"       <td>",
"        pH 4 incubation, 20 nm virus filtration, depth filtration, TSE removal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     S/D: solvent/detergent treated; PEG: polyethylene glycol; NF: nanofiltration; TSE: transmissable spongiform encephalopathy.",
"     <br>",
"      * Units as reported by manufacturer.&nbsp; Other stabilizing components may be present. Consult product labeling.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Osmolality varies depending on diluent type, volume, and protein concentration.",
"       <br>",
"        &Delta;&nbsp;Privigen is contraindicated in patients with hyperprolinemia.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: United States Food &amp; Drug Administration&nbsp;licensed product information accessible at:",
"     <a href=\"file://dailymed.nlm.nih.gov/dailymed/about.cfm\">",
"      file://dailymed.nlm.nih.gov/dailymed/about.cfm",
"     </a>",
"     &nbsp;or data&nbsp;available upon request&nbsp;from manufacturer's medical information department.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_478=[""].join("\n");
var outline_f0_29_478=null;
var title_f0_29_479="Fetal polymicrogyria";
var content_f0_29_479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal polymicrogyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 217px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Third trimester fetus with diffusely dysmorphic sawtooth pattern of the gyri over the convexities compatible with polymicrogyria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_29_479=[""].join("\n");
var outline_f0_29_479=null;
